[go: up one dir, main page]

CN1579485B - Traditional Chinese medicine composition for treating intestinal dysfunction and preparation method thereof - Google Patents

Traditional Chinese medicine composition for treating intestinal dysfunction and preparation method thereof Download PDF

Info

Publication number
CN1579485B
CN1579485B CN 200410014337 CN200410014337A CN1579485B CN 1579485 B CN1579485 B CN 1579485B CN 200410014337 CN200410014337 CN 200410014337 CN 200410014337 A CN200410014337 A CN 200410014337A CN 1579485 B CN1579485 B CN 1579485B
Authority
CN
China
Prior art keywords
grams
composition
radix
extract
bupleurum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN 200410014337
Other languages
Chinese (zh)
Other versions
CN1579485A (en
Inventor
杨星昊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Normal University
Original Assignee
Nanjing Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Normal University filed Critical Nanjing Normal University
Priority to CN 200410014337 priority Critical patent/CN1579485B/en
Publication of CN1579485A publication Critical patent/CN1579485A/en
Application granted granted Critical
Publication of CN1579485B publication Critical patent/CN1579485B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

治疗肠功能紊乱的中药组合物包括以下组分:柴胡6-18克,白芍6-30克,太子参3-18克,甘草6-15克。该基本方可以不添加组分直接在临床使用;也可以上述中药组合物的提取物作为药物;所说的提取物是指:a、提取上述组合物的挥发油备用;b、对上述提取挥发油后的组合物采用水、乙醇、或其它有机溶剂提取;c、纯化分离:水提取液,真空浓缩,乙醇沉淀,树脂吸附,树脂交换,高速离心,环糊精包合等方法得到的提取物;d、将上述各步骤的提取物合并,成为药物组合物。还可以增加白术、川芎、茯苓、葛根、钩藤、枳实等药物或其提取物;或是思密达、多潘立酮等化合物。本发明还提供了以上药物的制备方法。

Figure 200410014337

The traditional Chinese medicine composition for treating intestinal dysfunction comprises the following components: 6-18 grams of Bupleurum bupleuri, 6-30 grams of white peony, 3-18 grams of heterophylla, and 6-15 grams of licorice. This basic formula can be directly used clinically without adding components; the extract of the above-mentioned traditional Chinese medicine composition can also be used as medicine; said extract refers to: a, extracting the volatile oil of the above-mentioned composition for future use; The composition is extracted with water, ethanol, or other organic solvents; c, purification and separation: water extract, vacuum concentration, ethanol precipitation, resin adsorption, resin exchange, high-speed centrifugation, cyclodextrin inclusion and other methods to obtain the extract; d. Combining the extracts of the above steps to form a pharmaceutical composition. Drugs such as Atractylodes macrocephala, Chuanxiong, Poria cocos, kudzu root, uncaria, Citrus aurantii or their extracts can also be added; or compounds such as smecta and domperidone. The present invention also provides a preparation method of the above medicine.

Figure 200410014337

Description

治疗肠功能紊乱的中药组合物及其制备方法 Traditional Chinese medicine composition for treating intestinal dysfunction and preparation method thereof

技术领域technical field

本发明涉及一种治疗肠功能紊乱相关疾病的中药复方组合物及其现代制剂,以及制备这种药物组合物的工艺方法。The invention relates to a traditional Chinese medicine compound composition for treating diseases related to intestinal dysfunction and its modern preparation, as well as a process for preparing the pharmaceutical composition.

背景技术Background technique

肠易激综合征(irritable bowel syndrome,IBS)是常见消化道非器质性肠功能紊乱性疾病,具有慢性反复发作的临床特点。临床症状表现为腹部不适(腹痛、腹胀)和肠道运动异常,如排便习惯改变(腹泻或便秘)、大便性状异常(稀便、粘液便或硬结便)、排便次数增多为主要表现,且持续存在或间歇发作,病理检查多无特异性肠道炎性病变,临床分为腹泻型、便秘型、交替型。现代医学认为IBS的发病原因与精神因素、肠道动力学改变、饮食不节、结肠分泌和吸收功能改变、肠道菌群失调等有关,其病因和发病中涉及生物学和社会心理(包括紧张情绪、患者的性格与行为)等因素,被公认为一种心身疾病。目前治疗手段有限,多从松弛肠道平滑肌、激动和拮抗神经递质、抗焦虑出发,作用有限。且药物常常是针对处置如腹泻或便秘等单一症状,主要集中在对肠道微生态环节的调节、抗抑郁、促动力药治疗、钙通道拮抗剂以及收敛剂治疗等,由于本病发病涉及精神、饮食、个体素质多个方面,以上各类药物虽能缓解肠易激综合征的某些症状,在临床应用中均存在片面性和局限性,尚不能满足临床的要求。但在应用中存在着无法根治、副作用大、个体差异明显、治疗费用高等缺点。Irritable bowel syndrome (IBS) is a common non-organic intestinal dysfunction disease of the digestive tract, with clinical characteristics of chronic recurrent attacks. The clinical symptoms are abdominal discomfort (abdominal pain, bloating) and abnormal intestinal motility, such as changes in bowel habits (diarrhea or constipation), abnormal stool properties (loose stools, mucus stools, or hard stools), and increased frequency of bowel movements. Existence or intermittent attacks, pathological examination mostly no specific intestinal inflammatory lesions, clinically divided into diarrhea type, constipation type, alternating type. Modern medicine believes that the pathogenesis of IBS is related to mental factors, changes in intestinal dynamics, improper diet, changes in colon secretion and absorption, and intestinal flora imbalance. The etiology and pathogenesis involve biology and social psychology (including tension Emotion, patient's personality and behavior) and other factors are recognized as a psychosomatic disease. The current treatment methods are limited, mostly starting from relaxation of intestinal smooth muscle, stimulation and antagonism of neurotransmitters, and anti-anxiety, with limited effects. And the drugs are often aimed at treating single symptoms such as diarrhea or constipation, mainly focusing on the regulation of intestinal microecology, antidepressant, prokinetic drug treatment, calcium channel antagonist and astringent treatment, etc. , diet, and individual quality. Although the above types of drugs can relieve some symptoms of irritable bowel syndrome, they all have one-sidedness and limitations in clinical application and cannot meet clinical requirements. However, in application, there are disadvantages such as no cure, large side effects, obvious individual differences, and high treatment costs.

03112782.7号中国发明专利申请公开了一种“治疗肠功能紊乱疾病的中药组合物及其制剂”,该方案认为精神因素是肠功能紊乱的首要病因,应以“整体观念”和“辨证施治”的原则提供了如下配方:柴胡6-15克,白芍5-20克,川芎-10克,白术6-20克,茯苓6-12克,甘草5-20克。该方案的立意与效果均宜于临床实践,但根据经验,大多生产者会希望对该方案进一步简化,以便得到更宜于工业化大生产的的配方方案与生产工艺。No. 03112782.7 Chinese invention patent application discloses a "Chinese medicine composition and preparation for treating intestinal dysfunction diseases". The plan believes that mental factors are the primary cause of intestinal dysfunction, and should be treated with "holistic concept" and "syndrome differentiation" The principle provides the following formula: Bupleurum 6-15 grams, Paeoniae Alba 5-20 grams, Rhizoma Chuanxiong-10 grams, Atractylodes macrocephala 6-20 grams, Poria cocos 6-12 grams, licorice 5-20 grams. The idea and effect of this scheme are suitable for clinical practice, but based on experience, most manufacturers would like to further simplify the scheme in order to obtain a formula scheme and production process that are more suitable for industrialized mass production.

发明内容Contents of the invention

本发明全面综合该症侯群发病机理中的多因素,而提供的治疗肠易激综合征(IBS)等肠功能紊乱性疾病的中药复方组合物。IBS临床主要表现腹泻、便秘、腹痛、腹泻便秘交替;伴纳少、倦怠、消瘦、寐差、烦躁等。现代医学分为腹泻型、便秘型、交替型。本项目发明人在多年临床治疗和科研的基础上从中医理论出发,认为IBS常见和首要的原因是精神因素。病人往往精神紧张、抑郁、烦躁时发病或加重,属中医“七情”致病范畴,在此基础上总结出有关治疗原则和经临床验证的基本方。The invention comprehensively integrates multiple factors in the pathogenesis of the syndrome, and provides a traditional Chinese medicine compound composition for treating intestinal dysfunction diseases such as irritable bowel syndrome (IBS). The main clinical manifestations of IBS are diarrhea, constipation, abdominal pain, alternating diarrhea and constipation; accompanied by anorexia, fatigue, weight loss, poor sleep quality, irritability, etc. Modern medicine is divided into diarrhea type, constipation type, alternating type. Based on many years of clinical treatment and scientific research, the inventor of this project proceeds from the theory of traditional Chinese medicine and believes that the common and primary cause of IBS is mental factors. Patients often suffer from mental stress, depression, and irritability, and the disease is caused by the "seven emotions" of traditional Chinese medicine. Based on this, the relevant treatment principles and basic prescriptions that have been clinically verified are summarized.

上述治疗肠功能紊乱的中药组合物包括:The above-mentioned traditional Chinese medicine composition for treating intestinal dysfunction comprises:

柴胡    6-18克,Bupleurum 6-18 grams,

白芍    6-30克,Paeoniae Alba 6-30 grams,

太子参  6-18克,Pseudostellaria 6-18 grams,

甘草    6-15克。Licorice 6-15 grams.

以上基本方所用比例量为能够减轻、缓解或治愈有关适应症,调节肠胃道功能的各种药材量和药物组合的比例。根据临床症状的缓急轻重可采用以下比例。The proportions used in the above basic prescriptions are the proportions of various medicinal materials and drug combinations that can alleviate, relieve or cure relevant indications and regulate gastrointestinal function. The following ratios can be used according to the priority of clinical symptoms.

基本方优化用量1为:The basic square optimization amount 1 is:

柴胡    12-18克,Bupleurum 12-18 grams,

白芍    12-30克,Paeoniae Alba 12-30 grams,

太子参    6-12克,Pseudostellaria 6-12 grams,

甘草      6-12克。Licorice 6-12 grams.

基本方优化用量2为:The basic square optimization amount 2 is:

柴胡    9-12克,Bupleurum 9-12 grams,

白芍    9-12克,Paeoniae Alba 9-12 grams,

太子参  6-12克,Pseudostellaria 6-12 grams,

甘草    6-12克。Licorice 6-12 grams.

以上基本方可以有以下几种实施方式:The above basic methods can be implemented in the following ways:

1、不添加任何组分,直接在临床使用:该组合物即为配方;1. Do not add any components, directly use it in clinic: the composition is the formula;

2、以上述中药组合物的提取物作为药物;2. Using the extract of the above-mentioned traditional Chinese medicine composition as a medicine;

3、在上述基本方的基础上增加其它成分;3. Add other ingredients on the basis of the above basic formula;

4、在上述中药组合物的提取物的基础上增加其它成分。4. Adding other ingredients on the basis of the extract of the above-mentioned traditional Chinese medicine composition.

对以上2、3、4项分别说明如下:The above items 2, 3, and 4 are explained as follows:

其中“以上述中药组合物的提取物作为药物”,所说的“提取物”是指:Wherein "using the extract of the above-mentioned traditional Chinese medicine composition as a medicine", the "extract" refers to:

a、提取上述组合物的挥发油备用;A, extract the volatile oil of above-mentioned composition for subsequent use;

b、对上述提取挥发油后的组合物采用水、乙醇、或其它有机溶剂提取;b. The composition after the above-mentioned extraction of volatile oil is extracted with water, ethanol, or other organic solvents;

c、用水、乙醇、或其它有机溶剂提取后的组合物,采用真空浓缩,乙醇沉淀,树脂吸附,树脂交换,高速离心,环糊精包合等单独或组合的技术方法得到的提取物;c. The composition extracted with water, ethanol, or other organic solvents, the extract obtained by vacuum concentration, ethanol precipitation, resin adsorption, resin exchange, high-speed centrifugation, cyclodextrin inclusion, etc. alone or in combination;

d、将上述各步骤的提取物合并,成为药物组合物。d. Combining the extracts of the above steps to form a pharmaceutical composition.

挥发油部位(成分组合一):处方药物经粉碎,采用水蒸汽蒸馏的方法提取出的挥发性油状物质。收率为药材重量的0.5-3%。经GC-MS分析其中含多个组分(按含量从大到小顺序)包括:Volatile oil part (ingredient combination 1): the volatile oily substance extracted by steam distillation after the prescription drug is pulverized. The yield is 0.5-3% of the medicinal material weight. Through GC-MS analysis, it contains multiple components (in descending order of content) including:

苍术酮(Atractylon)、白术内酯A(Butenolide A)、白术内酯B(ButenolideB)、藁本内酯(ligustilide)及其衍生物、3-β-乙酰氧基苍术酮(3-β-Acetoxyatractylon)、芹烷二烯酮〔Selina-4(14),7(11)-dien-8-one〕、香会烯,苍术醇等。动物药效研究显示能明显抑制因新斯的明负荷小鼠引起的小肠功能亢进,改善阿托品引起的小肠功能受抑状态:可显著促进正常小鼠肠推进,增加脾虚小鼠脾指数、胸腺指数,显著减少由醋酸引起的小鼠扭体次数。对利血平所致的大鼠胃肠道功能紊乱影响的实验:大鼠利血平连续造模后,体重、摄食量、胸腺指数、脾指数、血浆和空肠组织匀浆中的MTL水平与正常对照组比较,显著降低(P<0.01)。不同部位的组分、组合物提取物给药组与模型组比较能不同程度地改善上述状况,其中体重、摄食量、胸腺指数、血浆和空肠组织匀浆中的MTL水平。粘膜损伤情况实验:不同部位的组分、组合物提取物的给药组与模型组相比较,均有显著差异(P<0.05)。Atractylon, Butenolide A, Butenolide B, Ligustilide and its derivatives, 3-β-Acetoxyatractylon ), apirene, atractyl alcohol, etc. Animal pharmacodynamic studies have shown that it can significantly inhibit the hyperfunction of the small intestine caused by neostigmine-loaded mice, and improve the suppressed state of small intestine function caused by atropine: it can significantly promote intestinal propulsion in normal mice, and increase spleen index and thymus index in mice with spleen deficiency , significantly reduced the number of writhing in mice induced by acetic acid. Experiments on the influence of reserpine-induced gastrointestinal dysfunction in rats: After continuous modeling with reserpine in rats, the body weight, food intake, thymus index, spleen index, MTL levels in plasma and jejunum homogenate were correlated with Compared with the normal control group, it was significantly lower (P<0.01). Compared with the model group, the administration groups of components and composition extracts from different parts can improve the above conditions to varying degrees, in which body weight, food intake, thymus index, plasma and MTL levels in jejunum homogenate. Mucosa damage test: There were significant differences between the administration group and the model group in the components of different parts and composition extracts (P<0.05).

二氯甲烷提取部位组分(成分组合二):处方药物采用二氯甲烷从石油醚不溶部分中提取,硅胶层析后所得的化学成分的组合物。Components extracted from dichloromethane (component combination 2): the composition of the chemical components obtained by extracting dichloromethane from the insoluble part of petroleum ether for prescription drugs and silica gel chromatography.

经HPLC、TLC,IR,NHR,MS,UV等分析其中主要含有3种以上生物碱化学成分包扩:四甲基吡嗪--川芎嗪(ligustrazine,tetramethylpyrazine-TMP),异亮氨酰结氨酸内酰胺,川芎哚(Perlolyrine)。动物药效研究显示能明显抑制因新斯的明负荷小鼠引起的小肠功能亢进,改善阿托品引起的小肠功能受抑状态:增加脾虚小鼠脾指数、胸腺指数,显著减少由醋酸引起的小鼠扭体次数。对利血平所致的大鼠胃肠道功能紊乱影响的实验:大鼠利血平连续造模后,体重、摄食量、胸腺指数、脾指数、血浆和空肠组织匀浆中的MTL水平与正常对照组比较,显著降低(P<0.01)。不同部位的组分、组合物提取物给药组与模型组比较能不同程度地改善上述状况,其中体重、摄食量、胸腺指数、血浆和空肠组织匀浆中的MTL水平。粘膜损伤情况实验:不同部位的组分、组合物提取物的给药组与模型组相比较,均有显著差异(P<0.05)。After analysis by HPLC, TLC, IR, NHR, MS, UV, etc., it mainly contains more than 3 kinds of alkaloid chemical components including: tetramethylpyrazine-ligustrazine (tetramethylpyrazine-TMP), isoleucyl knotamine Acid lactam, Perlolyrine. Animal pharmacodynamic studies have shown that it can significantly inhibit the hyperfunction of the small intestine caused by neostigmine-loaded mice, and improve the suppressed state of small intestine function caused by atropine: increase the spleen index and thymus index of mice with spleen deficiency, and significantly reduce the mice caused by acetic acid. Number of twists. Experiments on the influence of reserpine-induced gastrointestinal dysfunction in rats: After continuous modeling with reserpine in rats, the body weight, food intake, thymus index, spleen index, MTL levels in plasma and jejunum homogenate were correlated with Compared with the normal control group, it was significantly lower (P<0.01). Compared with the model group, the administration groups of components and composition extracts from different parts can improve the above conditions to varying degrees, in which body weight, food intake, thymus index, plasma and MTL levels in jejunum homogenate. Mucosa damage test: There were significant differences between the administration group and the model group in the components of different parts and composition extracts (P<0.05).

乙酸乙酯提取部位组分:处方药物采用乙酸乙酯从二氯甲烷不溶部分中提取,硅胶层析后所得的化学成分的组合物。共两组:EtOAC1成份组和EtOAC2成份组。Ethyl acetate extraction site components: prescription drugs are extracted from dichloromethane insoluble parts with ethyl acetate, and the composition of chemical components obtained after silica gel chromatography. There are two groups: EtOAC1 component group and EtOAC2 component group.

EtOAC1(成分组合三):经HPLC、TLC,IR,NHR,MS,UV等分析其中主要含有5种酚类化学成分。阿魏酸(ferculic acid),川芎内酯,川芎酚(chuanxiongol),大黄酚(chrysophanol),牡丹酚(paeonel)。EtOAC1 (component combination 3): It mainly contains 5 kinds of phenolic chemical components through HPLC, TLC, IR, NHR, MS, UV and other analysis. Ferulic acid, chuanxiongolide, chuanxiongol, chrysophanol, paeonel.

动物药效研究显示能明显抑制因新斯的明负荷小鼠引起的小肠功能亢进,改善阿托品引起的小肠功能受抑状态:可显著促进正常小鼠肠推进,增加脾虚小鼠脾指数、胸腺指数,显著减少由醋酸引起的小鼠扭体次数。对利血平所致的大鼠胃肠道功能紊乱影响的实验:大鼠利血平连续造模后,体重、摄食量、胸腺指数、脾指数、血浆和空肠组织匀浆中的MTL水平与正常对照组比较,显著降低(P<0.01)。不同部位的组分、组合物提取物给药组与模型组比较能不同程度地改善上述状况,其中体重、摄食量、胸腺指数、血浆和空肠组织匀浆中的MTL水平。粘膜损伤情况实验:不同部位的组分、组合物提取物的给药组与模型组相比较,均有显著差异(P<0.05)。Animal pharmacodynamic studies have shown that it can significantly inhibit the hyperfunction of the small intestine caused by neostigmine-loaded mice, and improve the suppressed state of small intestine function caused by atropine: it can significantly promote intestinal propulsion in normal mice, and increase spleen index and thymus index in mice with spleen deficiency , significantly reduced the number of writhing in mice induced by acetic acid. Experiments on the influence of reserpine-induced gastrointestinal dysfunction in rats: After continuous modeling with reserpine in rats, the body weight, food intake, thymus index, spleen index, MTL levels in plasma and jejunum homogenate were correlated with Compared with the normal control group, it was significantly lower (P<0.01). Compared with the model group, the administration groups of components and composition extracts from different parts can improve the above conditions to varying degrees, in which body weight, food intake, thymus index, plasma and MTL levels in jejunum homogenate. Mucosa damage test: There were significant differences between the administration group and the model group in the components of different parts and composition extracts (P<0.05).

EtOAC2(成分组合四)。经HPLC、TLC,IR,NHR,MS,UV等分析其中主要含以下化学成分。柴胡皂甙元A-G(saikogenin A-G),甘草次酸(glycyrrhetinic acid),甘草苷元(liquiritigenin),异甘草苷元(liquiritigenin),山柰酚(Kaempferol),异甘草素(isoliquiritigenin),槲皮素(quercetin),异槲皮素(isoquercetin),异鼠李素(isorhamnetin)等。动物药效研究显示能明显抑制因新斯的明负荷小鼠引起的小肠功能亢进,改善阿托品引起的小肠功能受抑状态:可显著促进正常小鼠肠推进,增加脾虚小鼠脾指数、胸腺指数,显著减少由醋酸引起的小鼠扭体次数。对利血平所致的大鼠胃肠道功能紊乱影响的实验:大鼠利血平连续造模后,体重、摄食量、胸腺指数、脾指数、血浆和空肠组织匀浆中的MTL水平与正常对照组比较,显著降低(P<0.01)。不同部位的组分、组合物提取物给药组与模型组比较能不同程度地改善上述状况,其中体重、摄食量、胸腺指数、血浆和空肠组织匀浆中的MTL水平。粘膜损伤情况实验:不同部位的组分、组合物提取物的给药组与模型组相比较,均有显著差异(P<0.05)。EtOAC2 (component combination four). Analyzed by HPLC, TLC, IR, NHR, MS, UV, etc., it mainly contains the following chemical components. Saikogenin A-G (saikogenin A-G), glycyrrhetinic acid, liquiritigenin, isoliquiritigenin, kaempferol, isoliquiritigenin, quercetin (quercetin), different quercetin (isoquercetin), different rhamnetin (isorhamnetin) and so on. Animal pharmacodynamic studies have shown that it can significantly inhibit the hyperfunction of the small intestine caused by neostigmine-loaded mice, and improve the suppressed state of small intestine function caused by atropine: it can significantly promote intestinal propulsion in normal mice, and increase spleen index and thymus index in mice with spleen deficiency , significantly reduced the number of writhing in mice induced by acetic acid. Experiments on the influence of reserpine-induced gastrointestinal dysfunction in rats: After continuous modeling with reserpine in rats, the body weight, food intake, thymus index, spleen index, MTL levels in plasma and jejunum homogenate were correlated with Compared with the normal control group, it was significantly lower (P<0.01). Compared with the model group, the administration groups of components and composition extracts from different parts can improve the above conditions to varying degrees, in which body weight, food intake, thymus index, plasma and MTL levels in jejunum homogenate. Mucosa damage test: There were significant differences between the administration group and the model group in the components of different parts and composition extracts (P<0.05).

正丁醇提取部位有关组分:处方药物采用正丁醇从乙酸乙酯不溶部分的提取,硅胶层析后所得的化学成分的组合物。共两组:BuoH1成份组和BuoH2成份组。Relevant components of the n-butanol extraction part: the composition of chemical components obtained by extracting n-butanol from the insoluble part of ethyl acetate and silica gel chromatography for prescription drugs. There are two groups: BuoH1 component group and BuoH2 component group.

BuoH1(成分组合五):经HPLC、TLC,IR,NHR,MS,UV等分析其中主要含有黄酮及其苷类:新西兰牡荆甙II,甘草苷(liquiritin),异甘草苷(isoliquiritin),新甘草苷(neoliquiritin),异甘草素(isoliquiritigenin),芸香甙(Rutin)、山柰酚的苷类:山柰苷(kaempferitrin)、山柰酚-7-鼠李糖甙(Kaempferol-7-rhamnoside)、山柰酚-3-0-α-L-呋喃阿拉伯糖甙-7-0-α-L-吡喃鼠李糖甙、水仙甙(narcissin)。动物药效研究显示能明显抑制因新斯的明负荷小鼠引起的小肠功能亢进,改善阿托品引起的小肠功能受抑状态:可显著促进正常小鼠肠推进,增加脾虚小鼠脾指数、胸腺指数,显著减少由醋酸引起的小鼠扭体次数。对利血平所致的大鼠胃肠道功能紊乱影响的实验:大鼠利血平连续造模后,体重、摄食量、胸腺指数、脾指数、血浆和空肠组织匀浆中的MTL水平与正常对照组比较,显著降低(P<0.01)。不同部位的组分、组合物提取物给药组与模型组比较能不同程度地改善上述状况,其中体重、摄食量、胸腺指数、血浆和空肠组织匀浆中的MTL水平。粘膜损伤情况实验:不同部位的组分、组合物提取物的给药组与模型组相比较,均有显著差异(P<0.05)。BuoH1 (component combination five): analyzed by HPLC, TLC, IR, NHR, MS, UV, etc. It mainly contains flavonoids and their glycosides: New Zealand vitexin II, liquiritin, isoliquiritin, new Liquiritin (neoliquiritin), isoliquiritigenin (isoliquiritigenin), rutin (Rutin), glycosides of kaempferol: kaempferitrin, kaempferol-7-rhamnoside , kaempferol-3-0-α-L-arabinofuranoside-7-0-α-L-rhamnopyranoside, narcissin. Animal pharmacodynamic studies have shown that it can significantly inhibit the hyperfunction of the small intestine caused by neostigmine-loaded mice, and improve the suppressed state of small intestine function caused by atropine: it can significantly promote intestinal propulsion in normal mice, and increase spleen index and thymus index in mice with spleen deficiency , significantly reduced the number of writhing in mice induced by acetic acid. Experiments on the influence of reserpine-induced gastrointestinal dysfunction in rats: After continuous modeling with reserpine in rats, the body weight, food intake, thymus index, spleen index, MTL levels in plasma and jejunum homogenate were correlated with Compared with the normal control group, it was significantly lower (P<0.01). Compared with the model group, the administration groups of components and composition extracts from different parts can improve the above conditions to varying degrees, in which body weight, food intake, thymus index, plasma and MTL levels in jejunum homogenate. Mucosa damage test: There were significant differences between the administration group and the model group in the components of different parts and composition extracts (P<0.05).

BuoH2(成分组合六)。经HPLC、TLC,IR,NHR,MS,UV等分析其中主要含皂甙或萜甙类化学成分:甘草酸(glycyrrhizin),甘草皂甙A-K(glycyrrhizin A-K),柴胡皂甙A-F(saikosaponin A-F),芍药甙(paeoniflorin),芍药花甙(paeonin),芍药内酯甙(albiforin),氧化芍药甙(oxypaeoniflorin),羟基芍药甙,苯甲酰芍药甙(benzoylpaeoniflorin),牡丹酚甙(paeonoside)太子参皂甙A(pseudostellarinoside A)、尖叶丝石竹皂甙D(acutifoliside D)。动物药效研究显示能明显抑制因新斯的明负荷小鼠引起的小肠功能亢进,改善阿托品引起的小肠功能受抑状态:可显著促进正常小鼠肠推进,增加脾虚小鼠脾指数、胸腺指数,显著减少由醋酸引起的小鼠扭体次数。对利血平所致的大鼠胃肠道功能紊乱影响的实验:大鼠利血平连续造模后,体重、摄食量、胸腺指数、脾指数、血浆和空肠组织匀浆中的MTL水平与正常对照组比较,显著降低(P<0.01)。不同部位的组分、组合物提取物给药组与模型组比较能不同程度地改善上述状况,其中体重、摄食量、胸腺指数、血浆和空肠组织匀浆中的MTL水平。粘膜损伤情况实验:不同部位的组分、组合物提取物的给药组与模型组相比较,均有显著差异(P<0.05)。BuoH2 (ingredient combination six). Through HPLC, TLC, IR, NHR, MS, UV and other analysis, the main chemical components containing saponins or terpene glycosides: glycyrrhizin (glycyrrhizin), glycyrrhizin A-K (glycyrrhizin A-K), saikosaponin A-F (saikosaponin A-F), paeoniflorin (paeoniflorin), paeoniflorin (paeonin), paeoniflorin (albiforin), oxidized paeoniflorin (oxypaeoniflorin), hydroxypaeoniflorin, benzoylpaeoniflorin (benzoylpaeoniflorin), paeonoside (paeonoside) heterophylla saponin A ( pseudostellarinoside A), acutifoliside D (acutifoliside D). Animal pharmacodynamic studies have shown that it can significantly inhibit the hyperfunction of the small intestine caused by neostigmine-loaded mice, and improve the suppressed state of small intestine function caused by atropine: it can significantly promote intestinal propulsion in normal mice, and increase spleen index and thymus index in mice with spleen deficiency , significantly reduced the number of writhing in mice induced by acetic acid. Experiments on the influence of reserpine-induced gastrointestinal dysfunction in rats: After continuous modeling with reserpine in rats, the body weight, food intake, thymus index, spleen index, MTL levels in plasma and jejunum homogenate were correlated with Compared with the normal control group, it was significantly lower (P<0.01). Compared with the model group, the administration groups of components and composition extracts from different parts can improve the above conditions to varying degrees, in which body weight, food intake, thymus index, plasma and MTL levels in jejunum homogenate. Mucosa damage test: There were significant differences between the administration group and the model group in the components of different parts and composition extracts (P<0.05).

水溶性组分(成分组合七):处方药物采用纯净水从正丁醇不溶部分中提取,经乙醇沉淀,鞣酸或离子交换树脂脱蛋白后得到总多糖,经葡聚糖凝胶层析(Sephadex G-100)处理得到分子量为150000,120000,90000,46000,32000,15000的单个组分,水解后经纸色谱分析,检出半乳糖,葡萄糖,鼠李糖,阿拉伯糖,及半乳糖醛酸,葡萄糖醛酸。经HPLC、TLC,IR,NHR,MS,UV等分析其中主要含茯苓糖(pachymic acid)、茯苓聚糖(β-pachyman)、茯苓次聚糖(β-pachymaran)、甘草多糖(glycyrrizan UC)的多糖大分子成分的组合物。动物药效研究显示能明显抑制因新斯的明负荷小鼠引起的小肠功能亢进,改善阿托品引起的小肠功能受抑状态:可显著促进正常小鼠肠推进,增加脾虚小鼠脾指数、胸腺指数,显著减少由醋酸引起的小鼠扭体次数。对利血平所致的大鼠胃肠道功能紊乱影响的实验:大鼠利血平连续造模后,体重、摄食量、胸腺指数、脾指数、血浆和空肠组织匀浆中的MTL水平与正常对照组比较,显著降低(P<0.01)。不同部位的组分、组合物提取物给药组与模型组比较能不同程度地改善上述状况,其中体重、摄食量、胸腺指数、血浆和空肠组织匀浆中的MTL水平。粘膜损伤情况实验:不同部位的组分、组合物提取物的给药组与模型组相比较,均有显著差异(P<0.05)。Water-soluble components (ingredient combination seven): Prescription drugs are extracted from the n-butanol insoluble part with purified water, and the total polysaccharides are obtained after ethanol precipitation, tannic acid or ion exchange resin deproteinization, and are subjected to Sephadex gel chromatography ( Sephadex G-100) treatment to obtain individual components with molecular weights of 150000, 120000, 90000, 46000, 32000, 15000, after hydrolysis, galactose, glucose, rhamnose, arabinose, and galacturaldehyde were detected by paper chromatography acid, glucuronic acid. Analyzed by HPLC, TLC, IR, NHR, MS, UV, etc., which mainly contain pachymic acid, β-pachyman, β-pachymaran, and glycyrrhizan UC. Composition of polysaccharide macromolecular components. Animal pharmacodynamic studies have shown that it can significantly inhibit the hyperfunction of the small intestine caused by neostigmine-loaded mice, and improve the suppressed state of small intestine function caused by atropine: it can significantly promote intestinal propulsion in normal mice, and increase spleen index and thymus index in mice with spleen deficiency , significantly reduced the number of writhing in mice induced by acetic acid. Experiments on the influence of reserpine-induced gastrointestinal dysfunction in rats: After continuous modeling with reserpine in rats, the body weight, food intake, thymus index, spleen index, MTL levels in plasma and jejunum homogenate were correlated with Compared with the normal control group, it was significantly lower (P<0.01). Compared with the model group, the administration groups of components and composition extracts from different parts can improve the above conditions to varying degrees, in which body weight, food intake, thymus index, plasma and MTL levels in jejunum homogenate. Mucosa damage test: There were significant differences between the administration group and the model group in the components of different parts and composition extracts (P<0.05).

采用以下提取方案可以得到以上各组分的不同组合:The following extraction schemes can be used to obtain different combinations of the above components:

提取物E及组分:中药复方组合物采用水提取,经适当浓缩后,加入不同浓度的乙醇,静置后离心,取上清液浓缩,得到。经HPLC、TLC,IR,NHR,MS,UV等分析其中主要含成分组合二、三、四、五、六。总固体收率为药材重量的14-18%。Extract E and its components: the traditional Chinese medicine compound composition is extracted with water, after being properly concentrated, ethanol of different concentrations is added, left to stand, centrifuged, and the supernatant is concentrated to obtain. Analysis by HPLC, TLC, IR, NHR, MS, UV, etc. mainly contains component combinations 2, 3, 4, 5, and 6. The total solid yield is 14-18% of the medicinal material weight.

提取物S及组分:中药复方组合物采用水提取,经适当浓缩后,经硅胶柱多次层析分别得到多个极性不同的成分组合,经HPLC、TLC,IR,NHR,MS,UV等分析分别为成分组合二、三、四、五、六、七。Extract S and components: The Chinese medicine compound composition is extracted with water, and after being properly concentrated, multiple combinations of components with different polarities are obtained through silica gel column chromatography for multiple times, and are tested by HPLC, TLC, IR, NHR, MS, UV Etc analysis is component combination 2, 3, 4, 5, 6, 7 respectively.

提取物L及组分:中药复方组合物采用水提取,经离子交换柱交换吸附得到多个不同的成分组合。经HPLC、TLC,IR,NHR,MS,UV等分析其中分别为成分组合二、三、四、五。Extract L and its components: the Chinese medicine compound composition is extracted with water, and exchanged and adsorbed by an ion exchange column to obtain a number of different component combinations. Analysis by HPLC, TLC, IR, NHR, MS, UV, etc., which are component combinations 2, 3, 4, and 5, respectively.

提取物G及组分:中药复方组合物采用水提取,经适当浓缩后,经高速离心处理后,溶于水溶液的组分。得到多个不同的成分组合。经HPLC、TLC,IR,NHR,MS,UV等分析其中分别为成分组合二、三、四、五。总固体收率为药材重量的18-24%。Extract G and its components: the Chinese medicine compound composition is extracted with water, after being properly concentrated and processed by high-speed centrifugation, the component is dissolved in the aqueous solution. A number of different ingredient combinations are obtained. Analysis by HPLC, TLC, IR, NHR, MS, UV, etc., which are component combinations 2, 3, 4, and 5, respectively. The total solid yield is 18-24% of the medicinal material weight.

提取物D及组分:中药复方组合物采用水提取,经大孔吸附树脂吸附后洗脱得到多个不同的成分组合。经HPLC、TLC,IR,NHR,MS,UV等分析其中分别为成分组合二、三、四、五、六、七。固体收率为药材重量的2.0-7.0%。Extract D and its components: the Chinese medicine compound composition is extracted with water, and then eluted after being adsorbed by a macroporous adsorption resin to obtain a number of different component combinations. Analyzed by HPLC, TLC, IR, NHR, MS, UV, etc., which are component combinations 2, 3, 4, 5, 6, and 7, respectively. The solid yield is 2.0-7.0% of the medicinal material weight.

提取物C及组分:中药复方组合物采用水提取,适当浓缩后,经高速离心,超滤处理后得到不同的成分组合,经HPLC、TLC,IR,NHR,MS,UV等分析其中分别为组合二、三、四、五、六、七。总固体收率为药材重量的10-15%。Extract C and its components: The Chinese medicine compound composition is extracted with water, concentrated properly, subjected to high-speed centrifugation and ultrafiltration to obtain different component combinations, which are analyzed by HPLC, TLC, IR, NHR, MS, UV, etc. Combinations two, three, four, five, six, seven. The total solid yield is 10-15% of the medicinal material weight.

水蒸汽蒸馏物及组分:中药复方组合物采用水蒸汽蒸馏的方法提取出的挥发性油状物质,收率为药材重量的1-3%。经GC-MS分析其中含成分组合一。经β-环糊精包合固体化储存备用。Steam distillate and components: the volatile oily substance extracted from the traditional Chinese medicine compound composition by steam distillation, and the yield is 1-3% of the weight of the medicinal material. GC-MS analysis contained component combination 1 therein. It is solidified and stored by β-cyclodextrin inclusion.

需要说明的是:上述各组分只是所述“提取物”的主要成分,其实际成分不限于此,应以其原料及提取方法限定该“提取物”。It should be noted that the above-mentioned components are only the main components of the "extract", and the actual components are not limited thereto. The "extract" should be limited by its raw materials and extraction methods.

以上第3、第4项所述的“在上述基本方的基础上增加其它成分;在上述中药组合物的提取物的基础上增加其它成分”,可以增加的组分有以下四类药物中的任意一种或多种。其中的植物性药物可以是采用相应植物(植物种以中国药典规定的植物种为准)为原料制备的各种炮制加工品。As mentioned in the above items 3 and 4, "Add other ingredients on the basis of the above basic prescription; add other ingredients on the basis of the extract of the above-mentioned traditional Chinese medicine composition", the components that can be added include the following four types of drugs: Any one or more. The botanical medicines can be various processed products prepared from corresponding plants (plant species specified in the Chinese Pharmacopoeia) as raw materials.

可增加的第一类药物:白术、川芎、茯苓、枳实、桂枝、陈皮、防风、、当归、半夏、黄连、大黄、黄芩、合欢皮中的1味或2味或3味,各组分的用量按药典所规定的一般用量,或采用以下具体处方用量。The first class of drugs that can be added: 1 or 2 or 3 of Atractylodes macrocephala, Chuanxiong, Poria, Citrus aurantium, Guizhi, Chenpi, Fangfeng, Angelica, Pinellia, Coptis, Rhubarb, Scutellaria, and Albizia Bark, each The dosage of the components is according to the general dosage stipulated in the Pharmacopoeia, or the following specific prescription dosage.

增加这类药品可以构成以下各方案:The addition of such drugs can constitute the following options:

处方1~5主要用于不同程度的腹泻、便秘、腹痛、腹泻便秘交替。Prescriptions 1 to 5 are mainly used for different degrees of diarrhea, constipation, abdominal pain, alternating diarrhea and constipation.

1、柴胡9克,白芍9克,太子参6克,甘草6克。1. Bupleurum 9 grams, white peony root 9 grams, heterophylla 6 grams, licorice 6 grams.

2、柴胡12克,白芍12克,太子参6克,甘草6克。2. 12 grams of bupleurum, 12 grams of white peony root, 6 grams of heterophylla, and 6 grams of licorice.

3、柴胡15克,白芍18克,太子参9克,甘草9克。3. 15 grams of Bupleurum, 18 grams of white peony root, 9 grams of heterophylla, and 9 grams of licorice.

4、柴胡12克,白芍27克,太子参6克,甘草9克。4. 12 grams of Bupleurum, 27 grams of white peony root, 6 grams of heterophylla, and 9 grams of licorice.

5、柴胡9克,白芍9克,太子参6克,白术9克,甘草6克。5. 9 grams of Bupleurum, 9 grams of white peony, 6 grams of heterophylla, 9 grams of Atractylodes macrocephala, and 6 grams of licorice.

处方6~10主要用于不同程度的腹泻、便秘、腹痛、腹泻便秘交替,并伴有较重程度的腹泻、疼痛症状。Prescriptions 6 to 10 are mainly used for different degrees of diarrhea, constipation, abdominal pain, alternating diarrhea and constipation, accompanied by severe diarrhea and pain symptoms.

6、柴胡9克,白芍9克,川芎6克,太子参6克,甘草6克。6. 9 grams of Bupleurum, 9 grams of white peony, 6 grams of Chuanxiong, 6 grams of heterophylla, and 6 grams of licorice.

7、柴胡9克,白芍18克,太子参6克、甘草9克,陈皮9克。7. 9 grams of Bupleurum, 18 grams of white peony root, 6 grams of heterophylla, 9 grams of licorice, and 9 grams of tangerine peel.

8、柴胡9克,白芍9克,太子参6克,甘草6克,枳实9克。8. Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Licorice 6 grams, Citrus aurantium 9 grams.

9、柴胡9克,白芍9克,太子参6克,甘草6克,黄芩9克。9. 9 grams of Bupleurum, 9 grams of white peony root, 6 grams of heterophylla, 6 grams of licorice, and 9 grams of skullcap.

10、柴胡9克,白芍12克,太子参6克,甘草6克、陈皮6-9克、防风6-9克。10. 9 grams of Bupleurum, 12 grams of white peony root, 6 grams of heterophylla, 6 grams of licorice, 6-9 grams of tangerine peel, and 6-9 grams of Fangfeng.

处方11~17主要用于腹泻、便秘或腹泻便秘交替,并伴有不同程度的寐差、烦躁等症状。Prescriptions 11 to 17 are mainly used for diarrhea, constipation or alternating diarrhea and constipation, accompanied by symptoms such as poor sleepiness and irritability in varying degrees.

11、柴胡9克,白芍9克,太子参6克、甘草6克、白术9克,防风6-9克。11. Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Licorice 6 grams, Atractylodes macrocephala 9 grams, Fangfeng 6-9 grams.

12、柴胡9克,白芍9克,太子参6克、甘草6克、白术9克、黄连6-9克。12. 9 grams of Bupleurum, 9 grams of white peony, 6 grams of heterophylla, 6 grams of licorice, 9 grams of Atractylodes macrocephala, and 6-9 grams of berberine.

13、柴胡9克,白芍9克,太子参6克、甘草6克、白术9克、茯苓9克。13. 9 grams of Bupleurum, 9 grams of white peony, 6 grams of heterophylla, 6 grams of licorice, 9 grams of Atractylodes macrocephala, and 9 grams of Poria.

14、柴胡9克,白芍9克,太子参6克、甘草6克、合欢皮9克。14. Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Licorice 6 grams, Albizia Julibrissin 9 grams.

15、柴胡9克,白芍9克,太子参6克,甘草6克,枳实6克。15. Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Licorice 6 grams, Citrus aurantium 6 grams.

16、柴胡9克,白芍9克,太子参6克,甘草6克,茯苓9,白术9克。16. 9 grams of Bupleurum, 9 grams of white peony root, 6 grams of heterophylla, 6 grams of licorice, 9 grams of Poria, and 9 grams of Atractylodes macrocephala.

17、柴胡9克,白芍9克,太子参6克,甘草6克,川芎6克。17. 9 grams of Bupleurum, 9 grams of white peony root, 6 grams of heterophylla, 6 grams of licorice, and 6 grams of Chuanxiong.

18、柴胡9克,白芍9克,太子参6克,甘草6克,大黄6克,半夏3克。18. 9 grams of Bupleurum, 9 grams of white peony root, 6 grams of heterophylla, 6 grams of licorice, 6 grams of rhubarb, and 3 grams of pinellia.

处方19~24主要用于腹泻、便秘或腹泻便秘交替,并伴有不同程度的腹涨、纳少、烦躁等症状Prescriptions 19-24 are mainly used for diarrhea, constipation or alternating diarrhea and constipation, accompanied by symptoms such as abdominal distension, anorexia, and irritability in varying degrees

19、柴胡9克,白芍9克,太子参6克,白术9克,甘草6克,枳实6克。19. 9 grams of Bupleurum, 9 grams of white peony, 6 grams of heterophylla, 9 grams of Atractylodes macrocephala, 6 grams of licorice, and 6 grams of aurantium.

20、柴胡9克,白芍9克,太子参6克,甘草6克,白术9克、黄连6-9克。20. 9 grams of Bupleurum, 9 grams of white peony, 6 grams of heterophylla, 6 grams of licorice, 9 grams of Atractylodes macrocephala, and 6-9 grams of berberine.

21、柴胡9克,白芍9克,太子参6克,甘草6克,陈皮6克,枳实6克。21. 9 grams of bupleurum, 9 grams of white peony root, 6 grams of heterophylla, 6 grams of licorice, 6 grams of tangerine peel, and 6 grams of aurantium.

22、柴胡9克,白芍9克,太子参6克,白术9克、甘草6克,黄芩9克,陈皮9克。22. 9 grams of Bupleurum, 9 grams of white peony, 6 grams of heterophylla, 9 grams of Atractylodes macrocephala, 6 grams of licorice, 9 grams of skullcap, and 9 grams of tangerine peel.

23、柴胡9克,白芍9克,太子参6克,白术9克、甘草6克,防风9克。23. 9 grams of Bupleurum, 9 grams of white peony, 6 grams of heterophylla, 9 grams of Atractylodes macrocephala, 6 grams of licorice, and 9 grams of Fangfeng.

24、柴胡9克,白芍9克,太子参6克,白术9克,甘草6克,川芎6克,茯苓9克。24. Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Atractylodes macrocephala 9 grams, Licorice 6 grams, Rhizoma Chuanxiong 6 grams, Poria cocos 9 grams.

处方25~28主要用于腹泻、便秘或腹泻便秘交替,并伴有不同程度的消瘦、畏寒等症。Prescriptions 25 to 28 are mainly used for diarrhea, constipation or alternating diarrhea and constipation, accompanied by varying degrees of emaciation and chills.

25、柴胡9克,白芍9克,太子参6克,白术9克,甘草6克,川芎6克。25. Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Atractylodes macrocephala 9 grams, Licorice 6 grams, Rhizoma Chuanxiong 6 grams.

26、柴胡9克,白芍9克,太子参6克,白术9克、甘草6克,当归6克,黄连3克。26. 9 grams of Bupleurum, 9 grams of white peony, 6 grams of heterophylla, 9 grams of Atractylodes macrocephala, 6 grams of licorice, 6 grams of angelica, and 3 grams of coptis.

27、白术9克,茯苓9克,甘草6克、柴胡6克,太子参6克、白芍12克、黄芪9克。27. 9 grams of Atractylodes macrocephala, 9 grams of poria, 6 grams of licorice, 6 grams of Bupleurum, 6 grams of heterophylla, 12 grams of white peony, and 9 grams of astragalus.

28、柴胡9克,白芍9克,太子参6克,白术9克,甘草6克,桂枝6克。28. 9 grams of Bupleurum, 9 grams of white peony, 6 grams of heterophylla, 9 grams of Atractylodes macrocephala, 6 grams of licorice, and 6 grams of cassia twig.

可增加的第二类药物:可以是以上第一类药物中某种或某些药物的提取物(各种药物组合物的水、乙醇或有机溶剂的提取物、一种及多种提取物或化学成分的组合体。包括一种及多种不同药物组合的提取物进行再次组合后的提取物组合体。)The second class of drugs that can be added: it can be the extract of one or some drugs in the above first class of drugs (extracts of water, ethanol or organic solvents of various pharmaceutical compositions, one or more extracts or Combinations of chemical components. Combinations of extracts that include one or more extracts of different drug combinations.)

所述的某种或某些药物的提取物(也可称为:“药物不同极性的化学成分组合和采用不同的分离方法得到的化学成分组合”)是指:挥发油部位、水提取液部位中的二氯甲烷提取组分、二氯甲烷不溶部分中的乙酸乙酯提取组分、乙酸乙酯不溶部分中的正丁醇提取组分、正丁醇不溶部位中的水溶性组分。见示意图(图1)。纯化分离干燥:水提取液,真空浓缩,乙醇沉淀,树脂吸附,树脂交换,高速离心,环糊精包合等单独或组合的技术方法得到的组分。见示意图(图2)。The extract of one or some drugs (also known as: "the combination of chemical components of different polarities of the drug and the combination of chemical components obtained by different separation methods") refers to: the volatile oil part, the water extract part The dichloromethane extract fraction in the dichloromethane insoluble fraction, the ethyl acetate extract fraction in the dichloromethane insoluble fraction, the n-butanol extract fraction in the ethyl acetate insoluble fraction, and the water-soluble fraction in the n-butanol insoluble fraction. See schematic diagram (Figure 1). Purification, separation and drying: water extract, vacuum concentration, ethanol precipitation, resin adsorption, resin exchange, high-speed centrifugation, cyclodextrin inclusion and other technical methods obtained alone or in combination. See schematic diagram (Figure 2).

可增加的第三类药物:可以是天然来源或人工合成的化合物。A third class of drugs that can be added: compounds that can be of natural origin or artificially synthesized.

例如,组合物加入以下之一的药物:思密达(SEMECDA)2-10g、多潘立酮(domperidone)5-20mg、西沙必利(cisapride)1-20mg、替加噻罗(Tegaserod)2-15mg、阿洛司琼(Alosetron)0.5-3mg、奥替溴铵(Spasmomen)50-200mg、匹维溴铵(Pinaverum bromide)50-200mg、马来酸曲美布汀(Trimebutine)0.2-1.5g、酪酸菌40-200mg等。For example, one of the following drugs is added to the composition: 2-10g of SEMECDA, 5-20mg of domperidone, 1-20mg of cisapride, 2-15mg of Tegaserod, Alosetron 0.5-3mg, Spasmomen 50-200mg, Pinaverum bromide 50-200mg, Trimebutine 0.2-1.5g, Butyric acid Bacteria 40-200mg, etc.

以上所述治疗肠功能紊乱中药组合物(和现代剂型)的制备方法,步骤如下:The preparation method of the above-mentioned Chinese medicine composition (and modern dosage form) for the treatment of intestinal dysfunction, the steps are as follows:

1、对上述组合物采用水、乙醇、或其它有机溶剂提取;1. The above composition is extracted with water, ethanol, or other organic solvents;

2、对上述水、乙醇、或其它有机溶剂提取后的组合物采用以下方法之一种或几种纯化分离:真空浓缩,乙醇沉淀,树脂吸附,树脂交换,高速离心,环糊精包合等技术方法处理后得到提取物;2. Use one or more of the following methods to purify and separate the above-mentioned composition extracted by water, ethanol, or other organic solvents: vacuum concentration, ethanol precipitation, resin adsorption, resin exchange, high-speed centrifugation, cyclodextrin inclusion, etc. The extract is obtained after the technical method is processed;

3、以上提取物合并,直接或再经纯化分离后加入适当的药用辅料,分别制备成颗粒剂、胶囊、片剂、口服液、注射剂类(皮下、血管、肌肉给药)、经皮肤或经粘膜给药制剂、直肠给药的栓剂;或者按步骤4:3. Combine the above extracts, add appropriate pharmaceutical excipients directly or after purification and separation, and prepare them into granules, capsules, tablets, oral liquids, injections (subcutaneous, blood vessel, intramuscular administration), transdermal or Transmucosal formulation, suppository for rectal administration; or follow step 4:

4、以上药物经粉碎后加入适当的药用辅料制备的颗粒剂、胶囊、片剂、经皮或经粘膜给药制剂、直肠给药的栓剂。4. Granules, capsules, tablets, preparations for transdermal or transmucosal administration, and suppositories for rectal administration prepared by adding appropriate pharmaceutical excipients to the above drugs after crushing.

以上中药组合物的适应症范围:The scope of indications of the above Chinese medicine composition:

人或其它哺乳动物的肠胃功能紊乱。包含:Gastrointestinal disorders in humans or other mammals. Include:

1、由精神因素诱发的肠易激综合症(肠功能紊乱)。1. Irritable bowel syndrome (bowel dysfunction) induced by mental factors.

2、由食物或炎症诱发的的肠易激综合症(肠功能紊乱)2. Irritable bowel syndrome (bowel dysfunction) induced by food or inflammation

3、IBS临床主要表现腹泻、便秘、腹痛、腹泻便秘交替;伴纳少、倦怠、消瘦、寐差、烦躁等。现代医学分为腹泻型、便秘型。临床症状以无规律的腹痛、腹胀、腹泻,大便性状改变及排便次数增多为主要表现。排除其他肠器质性疾病:排除甲状腺疾病、糖尿病、肾病、心血管病、造血系统疾病、溃疡性结肠炎、克隆氏病、慢性痢疾、消化性溃疡、慢性肝炎、肛门疾病等,防止假阳性。一般有以下特征(1)便前腹痛,便后缓解;(2)腹痛时肠蠕动明显增加;(3)便秘或腹泻;(4)全身状况一般良好或伴有全身性神经官能症表现。(5)结肠自发蠕动异常,肠敏感性增高。(6)内脏痛觉过敏等。3. The main clinical manifestations of IBS are diarrhea, constipation, abdominal pain, alternating diarrhea and constipation; accompanied by anorexia, fatigue, weight loss, poor sleep quality, irritability, etc. Modern medicine is divided into diarrhea type and constipation type. The main manifestations of clinical symptoms are irregular abdominal pain, abdominal distension, diarrhea, changes in stool properties and increased frequency of defecation. Exclude other intestinal organic diseases: exclude thyroid disease, diabetes, kidney disease, cardiovascular disease, hematopoietic system disease, ulcerative colitis, Crohn's disease, chronic dysentery, peptic ulcer, chronic hepatitis, anal disease, etc., to prevent false positives . Generally, it has the following characteristics: (1) abdominal pain before defecation, relieved after defecation; (2) intestinal peristalsis significantly increased during abdominal pain; (3) constipation or diarrhea; (4) generally good general condition or accompanied by systemic neurosis. (5) The spontaneous peristalsis of the colon is abnormal and the intestinal sensitivity is increased. (6) Visceral hyperalgesia, etc.

4、相关疾病包含:功能性肠紊乱(功能性腹泻、功能性便秘),急慢性功能性腹痛或腹胀或伴有胃部症状,周期性的腹痛或腹胀,功能性消化不良,胃痛胃部不适等。4. Related diseases include: functional bowel disorder (functional diarrhea, functional constipation), acute and chronic functional abdominal pain or bloating or accompanied by gastric symptoms, periodic abdominal pain or bloating, functional dyspepsia, stomach pain and stomach discomfort wait.

本发明组合物(包括以上所述,由提取物或含有化学药物的各种不同的组合)的动物药效学的研究结果:The results of the animal pharmacodynamics study of the composition of the present invention (comprising the above-mentioned, by extracts or various combinations containing chemical drugs):

药效学实验结果表明:The results of pharmacodynamic experiments show that:

1.对脾虚小鼠影响的实验不同部位的组分、组合物提取物能不同程度地显著增加脾虚小鼠的体重、摄食量,改善脾虚小鼠的体征、稀便级、增加脾虚小鼠脾指数、胸腺指数,调节脾虚小鼠的胃肠功能,与模型组比较有显著差异(P<0.05)。1. Experiments on the influence of mice with spleen deficiency. The components and composition extracts of different parts can significantly increase the body weight and food intake of mice with spleen deficiency to varying degrees, improve the signs and loose stools of mice with spleen deficiency, and increase the spleen quality of mice with spleen deficiency. Index and thymus index, which regulate the gastrointestinal function of mice with spleen deficiency, were significantly different from those in the model group (P<0.05).

2.对小鼠新斯的明负荷/阿托品负荷的小肠推进影响的实验:不同部位的组分、组合物提取物能不同程度地明显抑制因新斯的明负荷小鼠引起的小肠功能亢进,改善阿托品引起的小肠功能受抑状态,与模型组比较有显著差异(P<0.05),提示其对肠功能有双向调节作用。2. Experiments on the effects of neostigmine-loaded/atropine-loaded small intestine propulsion in mice: components and composition extracts from different parts can significantly inhibit the hyperfunction of the small intestine caused by neostigmine-loaded mice, Compared with the model group, it can improve the inhibited state of small intestinal function caused by atropine (P<0.05), suggesting that it has a two-way regulating effect on intestinal function.

3.对醋酸所致的小鼠扭体疼痛影响的实验:不同部位的组分、组合物提取物能不同程度地显著减少由醋酸引起的小鼠扭体次数。3. Experiments on the effect of acetic acid-induced writhing pain in mice: components and composition extracts from different parts can significantly reduce the number of writhing times in mice caused by acetic acid to varying degrees.

4.利血平所致的大鼠胃肠道功能紊乱影响的实验:大鼠利血平连续造模后,体重、摄食量、胸腺指数、脾指数、血浆和空肠组织匀浆中的MTL水平与正常对照组比较,显著降低(P<0.01)。不同部位的组分、组合物提取物给药组与模型组比较能不同程度地改善上述状况,其中体重、摄食量、胸腺指数、血浆和空肠组织匀浆中的MTL水平。4. Experiments on the effect of reserpine-induced gastrointestinal dysfunction in rats: After continuous modeling with reserpine in rats, body weight, food intake, thymus index, spleen index, MTL levels in plasma and jejunum homogenate Compared with the normal control group, it was significantly lower (P<0.01). Compared with the model group, the administration groups of components and composition extracts from different parts can improve the above conditions to varying degrees, in which body weight, food intake, thymus index, plasma and MTL levels in jejunum homogenate.

5.膜损伤情况实验:不同部位的组分、组合物提取物的给药组与模型组相比较,均有显著差异(P<0.05)。5. Membrane damage test: Compared with the model group, there were significant differences (P<0.05) between the administration group of components and composition extracts in different parts.

实验方法和结果Experimental Methods and Results

一、组合物提取物对脾虚小鼠的影响:1. Effect of composition extract on mice with spleen deficiency:

取昆明种雄性小鼠60只,随机分为6组。除正常对照组外,其余各组均给予大黄水煎液,复制小鼠脾虚模型。连续灌胃给药6d。0.1g·kg-1·d-1。不同部位的组分、组合物提取物与模型组比较,进行组间t检验。与阳性药组及模型组比较,能不同程度地显著增加脾虚小鼠的体重、摄食量,改善脾虚小鼠的体征、稀便级、增加脾虚小鼠脾指数、胸腺指数,调节脾虚小鼠的胃肠功能。结果见表2。Sixty Kunming male mice were randomly divided into 6 groups. Except for the normal control group, all other groups were given rhubarb water decoction to replicate the mouse model of spleen deficiency. Continuous intragastric administration for 6 days. 0.1g·kg -1 ·d -1 . The components and composition extracts of different parts were compared with the model group, and the inter-group t test was carried out. Compared with the positive drug group and the model group, it can significantly increase the body weight and food intake of mice with spleen deficiency to varying degrees, improve the signs and loose stools of mice with spleen deficiency, increase the spleen index and thymus index of mice with spleen deficiency, and regulate the Gastrointestinal function. The results are shown in Table 2.

表2组合物提取物对脾虚小鼠的影响(X±S)The influence of table 2 composition extract on mice with spleen deficiency (X ± S)

Figure G2004100143374D00151
Figure G2004100143374D00151

与对照组比较:P<0.05,△△P<0.01。与模型组比较:*P<0.05,**P<0.01。Compared with the control group: P<0.05, △△ P<0.01. Compared with the model group: * P<0.05, ** P<0.01.

二、组合物提取物对小鼠新斯的明负荷/阿托品负荷的小肠推进的影响:2. The effect of the composition extract on the small intestine propulsion of mouse neostigmine load/atropine load:

取昆明种小鼠60只,按体重随机分为6组。灌胃给药,连续5d。除正常对照组外,其余各组小鼠均皮下注射新斯的明1mg·kg-1。所有小鼠均灌胃5%的碳末0.1ml·10g-1,处死剖腹取出胃肠段,记录碳墨前沿至幽门的距离,计算其占小肠全长的百分比。各不同部位的组分、组合物提取物与模型组比较,进行组间t检验。另阿托品负荷的小肠推进实验方法同新斯的明负荷小肠推进实验,除模型组和给药组皮下注射阿托品5mg·kg-1负荷。结果见表3。Sixty Kunming mice were randomly divided into 6 groups according to body weight. Oral administration, continuous 5d. Except for the normal control group, the mice in other groups were subcutaneously injected with neostigmine 1 mg·kg -1 . All mice were fed with 5% carbon powder 0.1ml·10g -1 , sacrificed by laparotomy, and the gastrointestinal tract was taken out. The distance from the front of the carbon ink to the pylorus was recorded, and its percentage in the total length of the small intestine was calculated. The components and composition extracts of different parts were compared with the model group, and the inter-group t test was carried out. In addition, the method of atropine-loaded intestinal propulsion test was the same as that of neostigmine-loaded small-intestine propulsion test, except that the model group and the treatment group were subcutaneously injected with atropine 5 mg·kg -1 load. The results are shown in Table 3.

给药组和阳性药组与模型组比较,能不同程度地明显抑制因新斯的明负荷小鼠引起的小肠功能亢进,改善阿托品引起的小肠功能受抑状态,提示其对肠功能有双向调节作用。Compared with the model group, the administration group and the positive drug group can significantly inhibit the hyperfunction of the small intestine caused by neostigmine-loaded mice to varying degrees, and improve the inhibited state of small intestine function caused by atropine, suggesting that it has a two-way regulation on intestinal function effect.

表3组合物提取物对小鼠新斯的明负荷/阿托品负荷的小肠推进的影响(X±S)The effect of table 3 composition extract on the small intestine propulsion of mouse neostigmine load/atropine load (X ± S)

与对照组比较:P<0.05,△△P<0.01。与模型组比较:*P<0.05,**P<0.01。Compared with the control group: P<0.05, △△ P<0.01. Compared with the model group: * P<0.05, ** P<0.01.

三、组合物提取物对醋酸所致的小鼠扭体疼痛的影响:3. Effect of composition extract on mice writhing pain caused by acetic acid:

取昆明种小鼠,按体重分组。给药组分别给与不同组合物提取物。末次给药后,各鼠均腹腔注射0.6%醋酸溶液0.2ml/只,观察注射后15min内出现的扭体反应次数(腹部内凹、伸展后肢、臀部抬高),并计算镇痛百分率。结果见表4。不同部位的组分、组合物提取物和阳性药组与模型组比较,能不同程度地显著减少由醋酸引起的小鼠扭体次数。Take Kunming mice and divide them into groups according to body weight. The administration groups were given extracts of different compositions. After the last administration, each mouse was intraperitoneally injected with 0.6% acetic acid solution 0.2ml/only, observed the number of writhing reactions (abdominal concave, stretched hind limbs, buttocks raised) within 15 minutes after the injection, and calculated the analgesic percentage. The results are shown in Table 4. Compared with the model group, the components of different parts, composition extracts and positive drug groups can significantly reduce the number of mice writhing caused by acetic acid to varying degrees.

Figure G2004100143374D00162
Figure G2004100143374D00162

表4组合物提取物对醋酸所致的小鼠扭体疼痛的影响(X±S)The influence of table 4 composition extract on the mice writhing pain caused by acetic acid (X ± S)

Figure G2004100143374D00171
Figure G2004100143374D00171

与模型组比较:*P<0.05Compared with the model group: * P<0.05

四、组合物提取物对利血平所致的大鼠胃肠道功能紊乱的影响:4. Effect of composition extract on rat gastrointestinal dysfunction caused by reserpine:

取健康成年雄性SD大鼠,均分为6组。正常对照组腹腔注射生理盐水5ml·kg-1·d-1,其余各组腹腔注射利血平0.5mg·kg-1·d-1,同时不同部位的组分、组合物提取物分别给与不同组合物提取物,正常对照组及模型组灌胃等体积蒸馏水,1次·d-1,。给药过程中,随时观察大鼠的粪便及体征变化,并每日称量大鼠的体重、摄食量。连续14d后按MTL放射免疫试剂盒收集下列标本:血浆、空肠组织。随后立即取出各大鼠胸腺、脾脏,称重。将各不同部位的组分、组合物提取物与模型组比较,进行组间t检验,结果见表5,大鼠利血平连续造模14天后,体重、摄食量、胸腺指数、脾指数、血浆和空肠组织匀浆中的MTL水平与正常对照组比较,显著降低。不同部位的组分、组合物提取物的体重、摄食量、胸腺指数、血浆和空肠组织匀浆中的MTL水平与模型组相比较,均有明显差异。Healthy adult male SD rats were divided into 6 groups. The normal control group was intraperitoneally injected with normal saline 5ml·kg -1 ·d -1 , and the rest of the groups were intraperitoneally injected with reserpine 0.5mg·kg -1 ·d -1 . Extracts of different compositions were administered to the normal control group and the model group by intragastric administration of equal volumes of distilled water, once·d -1 . During the administration process, the feces and signs of the rats were observed at any time, and the body weight and food intake of the rats were weighed every day. After 14 consecutive days, the following samples were collected according to the MTL radioimmunoassay kit: plasma, jejunum tissue. Immediately afterward, the thymus and spleen of each rat were taken out and weighed. The components and composition extracts of different parts were compared with the model group, and the inter-group t test was carried out. The results are shown in Table 5. After 14 days of continuous modeling with reserpine in rats, the body weight, food intake, thymus index, spleen index, Compared with the normal control group, the MTL levels in plasma and jejunum homogenate were significantly lower. Compared with the model group, the components of different parts, the body weight of the composition extract, the food intake, the thymus index, the MTL level in plasma and jejunal tissue homogenate were significantly different.

表5组合物提取物对利血平所致的大鼠胃肠道功能紊乱的影响(X±S)The influence (X ± S) of the composition extract of table 5 on the rat gastrointestinal dysfunction caused by reserpine

与对照组比较:P<0.05,△△P<0.01。与模型组比较:*P<0.05,**P<0.01。Compared with the control group: P<0.05, △△ P<0.01. Compared with the model group: *P<0.05, **P<0.01.

五、组合物提取物对胃肠粘膜的损伤的影响:5. Effect of the composition extract on the damage of gastrointestinal mucosa:

取胃肠组织,肉眼、光镜、透射电镜观察粘膜损伤情况,结果见表6。Gastrointestinal tissues were collected, and the mucosal damage was observed with the naked eye, light microscope, and transmission electron microscope. The results are shown in Table 6.

表6胃肠粘膜的损伤观察Table 6 Observation of injury of gastrointestinal mucosa

Figure G2004100143374D00201
Figure G2004100143374D00201

临床使用观察:Clinical use observation:

本发明提供中药的复方组合物(包括以上所述,由提取物或含有化学药物的各种不同的组合)在中医理论和药理实验的基础上,经临床观察,用于IBS及其它肠胃功能紊乱疾病的治疗,效果较好。结果如下:The present invention provides a compound composition of traditional Chinese medicine (including the above-mentioned, various combinations of extracts or chemical drugs) for IBS and other gastrointestinal disorders on the basis of traditional Chinese medicine theory and pharmacological experiments and clinical observation. Disease treatment, the effect is better. The result is as follows:

对照药物的选择:Choice of control drug:

近年有多例临床报道采用思密达治疗IBS取得较好效果,思密达对IBS的多种症状均有改善作用,特别是在大便次数及大便性状方面,在服药后症状可得到迅速缓解和改善,大部分病人3-4天后大便可恢复正常。In recent years, there have been many cases of clinical reports using Smecta to treat IBS to achieve good results. Smecta can improve various symptoms of IBS, especially in terms of stool frequency and stool properties. After taking the medicine, the symptoms can be quickly relieved and Improvement, most patients can return to normal stool after 3-4 days.

病例选择标准:Case selection criteria:

挑选50例肠易激综合征病程在1个月以上的患者,病例选择:按罗马标准II选择确定。所有病例经血常规、便常规、肝功能、血糖、肝胆胰B超、纤维结肠镜或肠道钡剂造影排除器质性病变。临床表现以腹泻为主,伴有腹胀、肠鸣、腹痛、排便后腹痛可缓解。Select 50 patients with irritable bowel syndrome with a course of more than 1 month, case selection: according to Rome criteria II selection. In all cases, organic diseases were excluded by blood routine, stool routine, liver function, blood sugar, B-ultrasound of liver, gallbladder and pancreas, fiber colonoscopy or intestinal barium contrast. The clinical manifestations are mainly diarrhea, accompanied by abdominal distension, borborygmus, abdominal pain, which can be relieved after defecation.

治疗过程:Healing:

病例中男性39例,女性31例;分为治疗组50例,对照组20例。两组在性别、年龄、临床表现相近,有可比性。治疗组:用本发明处方每日一剂。治疗2周后症状改善者每日2次,再用2周。以4周后临床表现作为疗效判断的依据。对照组:思密达3克一次,每日3次,疗程同前。为非随机分组,治疗4周后查血常规、肝功能,治疗过程中每周复诊1次,了解症状改变、排便性状及次数,查便常规。Among the cases, there were 39 males and 31 females; they were divided into a treatment group of 50 cases and a control group of 20 cases. The two groups were similar in gender, age, and clinical manifestations and were comparable. Treatment group: with the prescription of the present invention, one dose per day. After 2 weeks of treatment, the symptoms improved twice a day, and then used for another 2 weeks. The clinical manifestations after 4 weeks were used as the basis for judging the curative effect. Control group: Smecta 3 grams once, 3 times a day, the course of treatment is the same as before. It is a non-random grouping. After 4 weeks of treatment, the blood routine and liver function will be checked. During the treatment, the patients will be followed up once a week to understand the changes in symptoms, the characteristics and frequency of defecation, and check the routine of stool.

疗效评定Efficacy evaluation

显效:腹泻停止,伴随症状明显缓解。有效:腹泻明显缓解,每日排便2次,伴随症状好转。无效:未达上述标准。Markedly effective: Diarrhea stopped, accompanied by obvious relief of symptoms. Effective: The diarrhea was obviously relieved, and the bowel movements were 2 times a day, accompanied by the improvement of the symptoms. Invalid: Does not meet the above criteria.

结果观察result observation

本发明处方组:50例,显效29例(58%),有效12例(24%),无效9例(18%),总有效率82%。对照组20例,显效4例(20%),有效7例(35%),无效9例(45%),总有效率55%。本发明处方疗效高于思密达,自拟方治疗最快起效为5天。3周疗效稳定,表明,腹痛和不适症状显著减少,肠道功能改善(包括大便次数和迫切感减少,大便性状改善),症状改善出现在用药的前四周内同时在整个用药期间得到保持。无效病例延长疗程亦不能提高疗效,两组用药均未见明显不良反应,治疗后血常规、肝功能均无变化。The prescription group of the present invention: 50 cases, 29 cases (58%) are markedly effective, 12 cases (24%) are effective, 9 cases (18%) are invalid, and the total effective rate is 82%. Of the 20 cases in the control group, 4 cases (20%) were markedly effective, 7 cases (35%) were effective, and 9 cases (45%) were ineffective, and the total effective rate was 55%. The curative effect of the prescription of the present invention is higher than that of Smecta, and the fastest onset of effect of self-prepared prescription treatment is 5 days. The curative effect was stable for 3 weeks, indicating that the symptoms of abdominal pain and discomfort were significantly reduced, and the intestinal function was improved (including the reduction of stool frequency and urgency, and the improvement of stool shape), and the symptom improvement appeared within the first four weeks of medication and was maintained throughout the medication period. Prolonging the course of treatment for ineffective cases could not improve the curative effect. No obvious adverse reactions were observed in the two groups of medications, and there was no change in blood routine and liver function after treatment.

附图说明Description of drawings

图1为不同化学部位分离示意图;Figure 1 is a schematic diagram of the separation of different chemical sites;

图2为本发明工艺流程图。Fig. 2 is a process flow chart of the present invention.

具体实施方式Detailed ways

实施例1,处方为:柴胡6克,白芍6克,太子参3克,甘草6克。Example 1, the prescription is: Bupleurum 6 grams, Radix Paeoniae Alba 6 grams, Radix Pseudostellariae 3 grams, Radix Glycyrrhizae 6 grams.

对上述组合物采用水、乙醇、或其它有机溶剂提取;The above composition is extracted with water, ethanol, or other organic solvents;

纯化分离干燥:水或乙醇的提取液经真空浓缩,乙醇沉淀,树脂吸附,树脂交换,高速离心,环糊精包合等方法得到的提取物;Purification, separation and drying: the extract of water or ethanol is obtained by vacuum concentration, ethanol precipitation, resin adsorption, resin exchange, high-speed centrifugation, cyclodextrin inclusion and other methods;

以上药物经粉碎后加入适当的药用辅料制备的颗粒剂、胶囊、片剂、经皮或经粘膜给药制剂、直肠给药的栓剂。Granules, capsules, tablets, preparations for transdermal or transmucosal administration, and suppositories for rectal administration prepared by adding appropriate pharmaceutical adjuvants to the above drugs.

实施例2,与实施例1基本相同,但处方为:柴胡18克,白芍30克,太子参18克,甘草15克。同时制备方法改为:Example 2 is basically the same as Example 1, but the prescription is: Bupleurum 18 grams, Radix Paeoniae Alba 30 grams, Radix Pseudostellariae 18 grams, Radix Glycyrrhizae 15 grams. At the same time, the preparation method is changed to:

对上述组合物采用水、乙醇、或其它有机溶剂提取;The above composition is extracted with water, ethanol, or other organic solvents;

纯化分离干燥:水或乙醇的提取液经真空浓缩,乙醇沉淀,树脂吸附,树脂交换,高速离心,环糊精包合等方法得到的提取物;Purification, separation and drying: the extract of water or ethanol is obtained by vacuum concentration, ethanol precipitation, resin adsorption, resin exchange, high-speed centrifugation, cyclodextrin inclusion and other methods;

以上提取物直接或经纯化分离后加入适当的药用辅料,分别制备成颗粒剂、胶囊、片剂、口服液、注射剂类、经皮或经粘膜给药制剂、直肠给药的栓剂。The above extracts are directly or purified and separated by adding appropriate pharmaceutical excipients to prepare granules, capsules, tablets, oral liquids, injections, transdermal or transmucosal administration preparations, and suppositories for rectal administration.

实施例3,与实施例1或2基本相同,但处方为:柴胡12克,白芍12克,太子参6克,甘草6克。Example 3 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 12 grams, Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.

实施例4,与实施例1或2基本相同,但处方为:柴胡18克,白芍30克,太子参12克,甘草12克。Example 4 is basically the same as Example 1 or 2, but the prescription is: Bupleurum bupleuri 18 grams, Radix Paeoniae Alba 30 grams, Radix Pseudostellariae 12 grams, Radix Glycyrrhizae 12 grams.

实施例5,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克, 甘草6克。Example 5 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Licorice 6 grams.

实施例6,与实施例1或2基本相同,但处方为:柴胡12克,白芍12克,太子参12克,甘草12克。Example 6 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 12 grams, Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 12 grams, Radix Glycyrrhiza 12 grams.

实施例7,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,甘草6克。Example 7 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.

实施例8,与实施例1或2基本相同,但处方为:柴胡12克,白芍12克,太子参6克,甘草6克。Example 8 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 12 grams, Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.

实施例9,与实施例1或2基本相同,但处方为:柴胡15克,白芍18克,太子参9克,甘草9克。Example 9 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 15 grams, Radix Paeoniae Alba 18 grams, Radix Pseudostellariae 9 grams, Radix Glycyrrhizae 9 grams.

实施例10,与实施例1或2基本相同,但处方为:柴胡12克,白芍27克,太子参6克,甘草9克。Example 10 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 12 grams, Radix Paeoniae Alba 27 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 9 grams.

实施例11,与实施例1或2基本相同,但处方为:柴胡12克,白芍12克,太子参6克,白术9克,甘草6克。Example 11 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 12 grams, Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 6 grams, Atractylodes Rhizome 9 grams, Radix Glycyrrhizae 6 grams.

实施例12,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,川芎6克,太子参6克,甘草6克。Example 12 is basically the same as Example 1 or 2, but the prescription is: Bupleuri 9 grams, Radix Paeoniae Alba 9 grams, Rhizoma Chuanxiong 6 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.

实施例13,与实施例1或2基本相同,但处方为:柴胡9克,白芍18克,太子参6克、甘草9克,陈皮9克。Example 13 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 18 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 9 grams, Chenpi 9 grams.

实施例14,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,甘草6克,枳实9克。Example 14 is basically the same as Example 1 or 2, but the prescription is: Bupleurum bupleuri 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Licorice 6 grams, Citrus aurantium 9 grams.

实施例15,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,甘草6克,黄芩9克。Example 15 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Scutellaria baicalensis 9 grams.

实施例16,与实施例1或2基本相同,但处方为:柴胡9克,白芍12克,太子参6克,甘草6克、陈皮6-9克、防风6-9克。Example 16 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 12 grams, Radix Pseudostellariae 6 grams, Licorice 6 grams, Chenpi 6-9 grams, Fangfeng 6-9 grams.

实施例17,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克、甘草6克、白术9克,防风6-9克。Example 17 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Atractylodes Rhizome 9 grams, Fangfeng 6-9 grams.

实施例18,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克、甘草6克、白术9克、黄连6-9克。Example 18 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Atractylodes Rhizome 9 grams, Coptidis 6-9 grams.

实施例19,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克、甘草6克、白术9克、茯苓9克。Example 19 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Atractylodes macrocephala 9 grams, Poria cocos 9 grams.

实施例20,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克、甘草6克、合欢皮9克、Example 20 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhiza 6 grams, Cortex Albiziae Julibrissin 9 grams,

实施例21,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,甘草6克,枳实6克。Example 21 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Citrus aurantium 6 grams.

实施例22,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,甘草6克,茯苓9,白术9克。Example 22 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Licorice 6 grams, Poria cocos 9 grams, Atractylodes macrocephala 9 grams.

实施例23,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,甘草6克,川芎6克。Example 23 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Licorice 6 grams, Rhizoma Chuanxiong 6 grams.

实施例24,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,白术9克,甘草6克,枳实6克。Example 24 is basically the same as Example 1 or 2, but the prescription is: Bupleurum bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Atractylodes macrocephala 9 grams, licorice 6 grams, Citrus aurantium 6 grams.

实施例25,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,甘草6克,白术9克、黄连6-9克。Example 25 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams, Atractylodes Rhizome 9 grams, Coptidis 6-9 grams.

实施例26,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,甘草6克,陈皮6克,枳实6克。Example 26 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Licorice 6 grams, Tangerine Peel 6 grams, Citrus Citrifolia 6 grams.

实施例27,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,白术9克、甘草6克,黄连6克,陈皮6克。Example 27 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Atractylodes Rhizome 9 grams, Licorice 6 grams, Coptidis 6 grams, and Chenpi 6 grams.

实施例28,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,白术9克、甘草6克,防风9克。Example 28 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Atractylodes Rhizome 9 grams, Licorice 6 grams, Fangfeng 9 grams.

实施例29,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,白术9克,甘草6克,川芎6克。Example 29 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Atractylodes Rhizome 9 grams, Licorice 6 grams, Rhizoma Chuanxiong 6 grams.

实施例30,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,白术9克、甘草6克,当归,黄连3克。Example 30 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Atractylodes Rhizoma Atractylodes Rhizome 9 grams, Licorice 6 grams, Angelica sinensis, Coptidis 3 grams.

实施例31,与实施例1或2基本相同,但处方为:白术9克,茯苓9克,甘草6克、柴胡6克,太子参6克、白芍12克、黄芩9克。Example 31 is basically the same as Example 1 or 2, but the prescription is: 9 grams of Atractylodes macrocephala, 9 grams of Poria cocos, 6 grams of licorice, 6 grams of Bupleurum, 6 grams of Radix Pseudostellariae, 12 grams of Radix Paeoniae Alba, and 9 grams of Scutellaria baicalensis.

实施例32,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,白术9克,甘草6克。Example 32 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Atractylodes Rhizome 9 grams, and Radix Glycyrrhizae 6 grams.

实施例33,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,白术9克,甘草6克,川芎6克,茯苓9克。Example 33 is basically the same as Example 1 or 2, but the prescription is: Bupleuri 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Atractylodes macrocephala 9 grams, Licorice 6 grams, Rhizoma Chuanxiong 6 grams, Poria cocos 9 grams.

实施例34,与实施例1或2基本相同,但处方为:柴胡9克,白芍9克,太子参6克,甘草6克。Example 34 is basically the same as Example 1 or 2, but the prescription is: Bupleurum 9 grams, Radix Paeoniae Alba 9 grams, Radix Pseudostellariae 6 grams, Radix Glycyrrhizae 6 grams.

参照图1、图2:对上述组合物采用水、乙醇、或其它有机溶剂提取;With reference to Fig. 1, Fig. 2: adopt water, ethanol or other organic solvent extraction to above-mentioned composition;

纯化分离干燥:水提取液,真空浓缩,乙醇沉淀,树脂吸附,树脂交换,高速离心,喷雾干燥、真空干燥、环糊精包合等方法得到的提取物;Purification, separation and drying: water extract, vacuum concentration, ethanol precipitation, resin adsorption, resin exchange, high-speed centrifugation, spray drying, vacuum drying, cyclodextrin inclusion and other methods to obtain the extract;

加入由白术9克、川芎6克、茯苓9克的水或乙醇提取物得到的组合物。The composition obtained by water or ethanol extract of 9 grams of Atractylodes macrocephala, 6 grams of Rhizoma Chuanxiong and 9 grams of Poria cocos is added.

以上药物经粉碎后加入适当的药用辅料制备的颗粒剂、胶囊、片剂、经皮或经粘膜给药制剂、直肠给药的栓剂。Granules, capsules, tablets, preparations for transdermal or transmucosal administration, and suppositories for rectal administration prepared by adding appropriate pharmaceutical adjuvants to the above drugs.

实施例35,与实施例34基本相同,但加入由白术9克、枳实9克的水或提取物得到的组合物。Example 35 is basically the same as Example 34, but a composition obtained by adding 9 grams of Atractylodes macrocephala and 9 grams of Citrus aurantium in water or an extract.

实施例36,与实施例34基本相同,但加入由防风9克、陈皮9克的水或提取物得到的组合物。Example 36 is basically the same as Example 34, but the composition obtained by adding water or extracts of 9 grams of Fangfeng and 9 grams of dried orange peel.

实施例37,与实施例34基本相同,但加入由黄连、枳实的水提取物。Example 37 is basically the same as Example 34, but the water extracts of Coptidis Rhizoma and Fructus Citrus Fructus are added.

实施例38,与实施例34基本相同,但加入由白术9克,防风6-9克的正丁醇提取物。Example 38 is basically the same as Example 34, but adding 9 grams of Atractylodes Rhizome and 6-9 grams of n-butanol extract of Fangfeng.

实施例40,与实施例34基本相同,但加入由枳实6克的乙酸乙脂提取物。Example 40, which is substantially the same as Example 34, but with the addition of 6 grams of ethyl acetate extract from Fructus Aurantii.

实施例41,与实施例34基本相同,但加入由陈皮6克,枳实6克的水提取物。Example 41 is substantially the same as Example 34, but adding 6 grams of tangerine peel and 6 grams of water extract of Citrus aurantium.

实施例42,与实施例34基本相同,但加入由白术9克、川芎6克的水提取物。Example 42 is basically the same as Example 34, but adding 9 grams of Atractylodes macrocephala and 6 grams of Rhizoma Chuanxiong water extract.

实施例43,与实施例1或2基本相同。柴胡9克,白芍9克,太子参6克,甘草6克。对上述组合物采用水、乙醇、或其它有机溶剂提取;Embodiment 43 is substantially the same as Embodiment 1 or 2. 9 grams of Bupleurum, 9 grams of white peony root, 6 grams of heterophylla, and 6 grams of licorice. The above composition is extracted with water, ethanol, or other organic solvents;

纯化分离干燥:水提取液,真空浓缩,乙醇沉淀,树脂吸附,树脂交换,高速离心,喷 雾干燥、真空干燥、环糊精包合等方法得到的提取物;Purification, separation and drying: water extract, vacuum concentration, ethanol precipitation, resin adsorption, resin exchange, high-speed centrifugation, spraying Extracts obtained by methods such as fog drying, vacuum drying, and cyclodextrin inclusion;

加入阿洛司琼(Alosetron)0.5-3mg,Add Alosetron (Alosetron) 0.5-3mg,

以上药物经粉碎后加入适当的药用辅料制备的颗粒剂、胶囊、片剂、经皮或经粘膜给药制剂、直肠给药的栓剂。Granules, capsules, tablets, preparations for transdermal or transmucosal administration, and suppositories for rectal administration prepared by adding appropriate pharmaceutical adjuvants to the above drugs.

实施例44,与实施例43基本相同,但将阿洛司琼改为多潘立酮(domperidone)5-20mg。Example 44 is basically the same as Example 43, but the alosetron is changed to 5-20 mg of domperidone.

实施例45,与实施例43基本相同,将阿洛司琼改为西沙必利(cisapride)1-20mg。Example 45 is basically the same as Example 43, except that alosetron is changed to cisapride (cisapride) 1-20 mg.

实施例46,与实施例43基本相同,将阿洛司琼改为替加噻罗(Tegaserod)2-15mg。Example 46 is basically the same as Example 43, except that alosetron is changed to 2-15 mg of Tegaserod.

实施例47,与实施例43基本相同,将阿洛司琼改为奥替溴铵(Spasmomen)50-200mg。Example 47 is basically the same as Example 43, except that alosetron is changed to otilonium bromide (Spasmomen) 50-200 mg.

实施例48,与实施例43基本相同,将阿洛司琼改为匹维溴铵(Pinaverumbromide)50-200mg。Example 48 is basically the same as Example 43, except that alosetron is changed to 50-200 mg of pinaverum bromide.

实施例49,与实施例43基本相同,将阿洛司琼改为马来酸曲美布汀(Trimebutine)0.2-1.5g。Example 49 is basically the same as Example 43, except that alosetron is changed to trimebutine maleate (Trimebutine) 0.2-1.5 g.

实施例50,与实施例43基本相同,将阿洛司琼改为酪酸菌40-200mg。Example 50 is basically the same as Example 43, except that alosetron is changed to 40-200 mg of butyric acid bacteria.

实施例51,柴胡9克,白芍9克,太子参6克、甘草6克、白术9克、经粉碎后,54000克,十倍水,100℃提取两次,每次一小时,合并提取液,减压浓缩(50℃,0.1M)至相对密度1。07,加入95%乙醇使溶液含醇量为50%,4℃存放24小时。取上清液喷雾干燥,总固体8100克,制备各种固体制剂;或取上清液配制液体制剂。Example 51, 9 grams of Radix Bupleurum, 9 grams of Radix Paeoniae Alba, 6 grams of Radix Pseudostellariae, 6 grams of Radix Glycyrrhizae, 9 grams of Atractylodes Rhizoma Rhizome, after crushing, 54,000 grams, ten times the amount of water, extracted twice at 100°C for one hour each time, combined The extract was concentrated under reduced pressure (50°C, 0.1M) to a relative density of 1.07, and 95% ethanol was added to make the solution alcohol content 50%, and stored at 4°C for 24 hours. Take the supernatant and spray dry it, the total solid is 8100g, to prepare various solid preparations; or take the supernatant to prepare liquid preparations.

实施例52,柴胡9克,白芍9克,太子参6克、甘草6克、白术9克经粉碎后,54000克,十倍水,100℃提取两次,每次一小时,合并提取液,先后通过阴离子交换树脂柱(弱碱型),阳离子交换树脂柱(强酸型)后,并分别用PH5。5醋酸缓冲液、PH9。0氨水缓冲液洗脱,洗脱液减压浓缩(50℃,-0.1M),真空干燥后得总固体1610克,制备各种固体制剂;或取浓缩液配制液体制剂。Example 52, 9 grams of Radix Bupleuri, 9 grams of Radix Paeoniae Alba, 6 grams of Radix Pseudostellariae, 6 grams of Radix Glycyrrhizae, and 9 grams of Atractylodes Rhizoma Rhizoma Rhizome, were crushed, extracted twice at 100°C with 54,000 grams of ten times water, each time for one hour, and combined extraction After passing through an anion exchange resin column (weak base type) and a cation exchange resin column (strong acid type) successively, they were eluted with PH5.5 acetate buffer solution and pH9.0 ammonia water buffer solution respectively, and the eluate was concentrated under reduced pressure ( 50°C, -0.1M), after vacuum drying, 1610 grams of total solids were obtained to prepare various solid preparations; or take the concentrated solution to prepare liquid preparations.

实施例53,柴胡9克,白芍9克,太子参6克、甘草6克、白术9克经粉碎后,54000克100℃提取两次,每次十倍水,一小时,合并提取液,先后通过大孔交换树脂柱(AB-8)后,并分别用20%,40%,60%,95%的乙醇溶液洗脱,洗脱液减压浓缩(50℃,-0.1Mpa),真空干燥后的总固体1730克,制备各种固体制剂;或取浓缩液配制液体制剂。Example 53: 9 grams of Radix Bupleurum, 9 grams of Radix Paeoniae Alba, 6 grams of Radix Pseudostellariae, 6 grams of Radix Glycyrrhizae, and 9 grams of Atractylodes Rhizoma Atractylodes Rhizome are crushed, extracted twice at 100°C with 54,000 grams of water, each time 10 times of water, for one hour, and combined the extracts , after successively passing through the macroporous exchange resin column (AB-8), and eluting with 20%, 40%, 60%, and 95% ethanol solution respectively, the eluate was concentrated under reduced pressure (50°C, -0.1Mpa), The total solid after vacuum drying is 1730 grams, and various solid preparations are prepared; or the concentrated solution is used to prepare liquid preparations.

实施例54,柴胡9克,白芍9克,太子参6克、甘草6克、白术9克经粉碎后,54000克100℃提取两次,每次十倍水,一小时,合并提取液,减压浓缩(50℃,-0.1Mpa)至相对密度1.07-1.10,4000~20000rpm离心20min,取上清液喷雾干燥后得总固体10220克,制备各种固体制剂;或取上清液配制液体制剂。Example 54: 9 grams of Radix Bupleuri, 9 grams of Radix Paeoniae Alba, 6 grams of Radix Pseudostellariae, 6 grams of Radix Glycyrrhizae, and 9 grams of Atractylodes Rhizoma Rhizoma Rhizome, were crushed, extracted twice at 100°C with 54,000 grams of water, each time 10 times of water, for one hour, and combined the extracts , concentrated under reduced pressure (50°C, -0.1Mpa) to a relative density of 1.07-1.10, centrifuged at 4000-20000rpm for 20min, and the supernatant was spray-dried to obtain a total solid of 10220 grams, and various solid preparations were prepared; or the supernatant was prepared liquid formulations.

实施例55,参照图1、图2:柴胡9克,白芍9克,太子参6克、甘草6克、白术9克经粉碎后,54000克100℃提取两次,每次十倍水,一小时,合并提取液,减压浓缩(50℃,-0.1Mpa)至相对密度1.07-1.10,4000~20000rpm,20min,取上清液通过50000M或10000M的超滤膜。取超滤液减压浓缩(50℃,-0.1Mpa),喷雾干燥后得总固体7030克制备各种固体制剂;或取超滤液配制针剂。Example 55, referring to Figure 1 and Figure 2: 9 grams of Bupleurum Radix, 9 grams of Radix Paeoniae Alba, 6 grams of Radix Pseudostellariae, 6 grams of Radix Glycyrrhizae, and 9 grams of Atractylodes Rhizoma Atractylodes Rhizoma Rhizoma Rhizome. , one hour, combine the extracts, concentrate under reduced pressure (50°C, -0.1Mpa) to a relative density of 1.07-1.10, 4000-20000rpm, 20min, take the supernatant and pass it through a 50000M or 10000M ultrafiltration membrane. Concentrate the ultrafiltrate under reduced pressure (50°C, -0.1Mpa), spray-dry to obtain 7030 g of total solids to prepare various solid preparations; or take the ultrafiltrate to prepare injections.

实施例56,柴胡9克,白芍9克,太子参6克、甘草6克、白术9克经粉碎后,54000克100℃提取两次,每次十倍水,一小时,合并提取液,减压浓缩(50℃,-0.1Mpa)至相对密 度1.35-1.40,加入少量硅胶混合,采用硅胶柱,20%,40%,60%,95%的乙醇溶液分段洗脱,各段洗脱液分别减压浓缩(50℃,-0.1Mpa),真空干燥后分别得到130克,320克,570克,598克固形物,制备各种固体制剂;或取浓缩液配制液体制剂。Example 56: 9 grams of Radix Bupleuri, 9 grams of Radix Paeoniae Alba, 6 grams of Radix Pseudostellariae, 6 grams of Radix Glycyrrhizae, and 9 grams of Atractylodes Rhizoma Atractylodes Rhizome are crushed, extracted twice at 100°C with 54,000 grams of water, each time ten times water, for one hour, and the extracts were combined , concentrated under reduced pressure (50°C, -0.1Mpa) to a relatively dense Degree 1.35-1.40, add a small amount of silica gel to mix, use silica gel column, 20%, 40%, 60%, 95% ethanol solution for segmental elution, and the eluent of each segment is concentrated under reduced pressure (50°C, -0.1Mpa) After vacuum drying, 130 grams, 320 grams, 570 grams, and 598 grams of solid matter were obtained respectively to prepare various solid preparations; or take the concentrated solution to prepare liquid preparations.

实施例57,柴胡9克,白芍9克,太子参6克、甘草6克、白术54000克经粉碎成粗颗粒后,加入十倍水,水蒸汽蒸馏提取5小时,收集馏出液,合并,向馏出液中加入食盐使饱和,放置24小时,分离油状物25克,加入200克β-环糊精,用胶体磨处理30分钟。真空干燥(50℃,-0.1Mpa)。得到白色固体206克,制备各种固体制剂。Example 57: 9 grams of Radix Bupleurum, 9 grams of Radix Paeoniae Alba, 6 grams of Radix Pseudostellariae, 6 grams of Radix Glycyrrhizae, and 54,000 grams of Atractylodes Rhizoma Rhizome were crushed into coarse particles, then ten times of water was added, extracted by steam distillation for 5 hours, and the distillate was collected. Merge, add salt to the distillate to make it saturated, leave it for 24 hours, separate 25 grams of oil, add 200 grams of β-cyclodextrin, and process it with a colloid mill for 30 minutes. Vacuum dried (50°C, -0.1Mpa). Obtain 206 grams of white solids, and prepare various solid preparations.

实施例58,以基本方为原料,取提取物E及组分作为药物:中药复方组合物采用水提取,经适当浓缩后,加入不同浓度的乙醇,静置后离心,取上清液浓缩,得到。经HPLC、TLC,IR,NHR,MS,UV等分析其中主要含成分组合二、三、四、五、六。总固体收率为药材重量的14-18%。Example 58, using the basic formula as the raw material, taking the extract E and its components as medicine: the Chinese medicine compound composition is extracted with water, after being properly concentrated, ethanol of different concentrations is added, left to stand and then centrifuged, and the supernatant is concentrated, get. Analysis by HPLC, TLC, IR, NHR, MS, UV, etc. mainly contains component combinations 2, 3, 4, 5, and 6. The total solid yield is 14-18% of the medicinal material weight.

实施例59,以基本方为原料,取提取物S及组分作为药物:中药复方组合物采用水提取,经适当浓缩后,经硅胶柱多次层析分别得到多个极性不同的成分组合,经HPLC、TLC,IR,NHR,MS,UV等分析分别为成分组合二、三、四、五、六、七。Example 59, using the basic formula as the raw material, taking the extract S and its components as medicine: the Chinese medicine compound composition is extracted with water, after being properly concentrated, multiple combinations of components with different polarities are respectively obtained by silica gel column chromatography , and analyzed by HPLC, TLC, IR, NHR, MS, UV, etc., are component combinations 2, 3, 4, 5, 6, and 7, respectively.

实施例60,以基本方为原料,取提取物L及组分作为药物:中药复方组合物采用水提取,经离子交换柱交换吸附得到多个不同的成分组合。经HPLC、TLC,IR,NHR,MS,UV等分析其中分别为成分组合二、三、四、五。Example 60, using the basic formula as the raw material, taking the extract L and its components as medicine: the Chinese medicine compound composition is extracted with water, and exchanged and adsorbed by an ion exchange column to obtain multiple different component combinations. Analysis by HPLC, TLC, IR, NHR, MS, UV, etc., which are component combinations 2, 3, 4, and 5, respectively.

实施例61,以基本方为原料,取提取物G及组分作为药物:中药复方组合物采用水提取,经适当浓缩后,经高速离心处理后,溶于水溶液的组分。得到多个不同的成分组合。经HPLC、TLC,IR,NHR,MS,UV等分析其中分别为成分组合二、三、四、五。总固体收率为药材重量的18-24%。Example 61, using the basic formula as the raw material, taking the extract G and its components as medicine: the Chinese medicine compound composition is extracted with water, after being properly concentrated, and subjected to high-speed centrifugation, the components are soluble in aqueous solution. A number of different ingredient combinations are obtained. Analysis by HPLC, TLC, IR, NHR, MS, UV, etc., which are component combinations 2, 3, 4, and 5, respectively. The total solid yield is 18-24% of the medicinal material weight.

实施例62,以基本方为原料,取提取物D及组分作为药物:中药复方组合物采用水提取,经大孔吸附树脂吸附后洗脱得到多个不同的成分组合。经HPLC、TLC,IR,NHR,MS,UV等分析其中分别为成分组合二、三、四、五、六、七。固体收率为药材重量的2.0-7.0%。Example 62, using the basic formula as the raw material, taking the extract D and its components as medicine: the Chinese medicine compound composition is extracted with water, adsorbed by a macroporous adsorption resin and then eluted to obtain multiple different component combinations. Analyzed by HPLC, TLC, IR, NHR, MS, UV, etc., which are component combinations 2, 3, 4, 5, 6, and 7, respectively. The solid yield is 2.0-7.0% of the medicinal material weight.

实施例63,以基本方为原料,取提取物C及组分作为药物:中药复方组合物采用水提取,适当浓缩后,经高速离心,超滤处理后得到不同的成分组合,经HPLC、TLC,IR,NHR,MS,UV等分析其中分别为成分组合二、三、四、五、六、七。总固体收率为药材重量的10-15%。Example 63, using the basic formula as the raw material, extract C and its components as medicine: the traditional Chinese medicine compound composition is extracted with water, concentrated properly, subjected to high-speed centrifugation, and treated with ultrafiltration to obtain different composition combinations, which are analyzed by HPLC and TLC , IR, NHR, MS, UV and other analysis, which are component combinations 2, 3, 4, 5, 6, and 7 respectively. The total solid yield is 10-15% of the medicinal material weight.

Claims (4)

1. a Chinese medicine composition for the treatment of bowel dysfunction is characterized in that, crude drug composed as follows:
Radix Bupleuri 6-18 gram,
Radix Paeoniae Alba 6-30 gram,
Radix Pseudostellariae 6-18 gram,
Radix Glycyrrhizae 6-15 gram.
2. according to the Chinese medicine composition of the described treatment bowel dysfunction of claim 1, it is characterized in that: the proportioning of each crude drug is:
Radix Bupleuri 12-18 gram,
Radix Paeoniae Alba 12-30 gram,
Radix Pseudostellariae 6-12 gram,
Radix Glycyrrhizae 6-12 gram.
3. according to the Chinese medicine composition of the described treatment bowel dysfunction of claim 1, it is characterized in that: the proportioning of each crude drug is:
Radix Bupleuri 9-12 gram,
Radix Paeoniae Alba 9-12 gram,
Radix Pseudostellariae 6-12 gram,
Radix Glycyrrhizae 6-12 gram.
4. according to the Chinese medicine composition of claim 2 or 3 described treatment bowel dysfunctions, it is characterized in that: said Chinese medicine composition is that a kind of extraction in by the following method obtains:
Water extraction is adopted in the combination of crude drug, after suitably concentrating, after high speed centrifugation is handled, gets water-soluble component; Or
Water extraction is adopted in the combination of crude drug, after suitably concentrating, and the extract that after high speed centrifugation, hyperfiltration treatment, obtains.
CN 200410014337 2004-03-16 2004-03-16 Traditional Chinese medicine composition for treating intestinal dysfunction and preparation method thereof Expired - Fee Related CN1579485B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200410014337 CN1579485B (en) 2004-03-16 2004-03-16 Traditional Chinese medicine composition for treating intestinal dysfunction and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200410014337 CN1579485B (en) 2004-03-16 2004-03-16 Traditional Chinese medicine composition for treating intestinal dysfunction and preparation method thereof

Publications (2)

Publication Number Publication Date
CN1579485A CN1579485A (en) 2005-02-16
CN1579485B true CN1579485B (en) 2010-04-28

Family

ID=34581704

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200410014337 Expired - Fee Related CN1579485B (en) 2004-03-16 2004-03-16 Traditional Chinese medicine composition for treating intestinal dysfunction and preparation method thereof

Country Status (1)

Country Link
CN (1) CN1579485B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101199639B (en) * 2007-12-20 2011-12-14 北京天力正元医药技术开发有限公司 Chinese medicine for treating irritable
KR101099004B1 (en) * 2009-03-13 2011-12-28 주식회사 사이그린 Composition for preventing or improving gastrointestinal diseases
CN101890082A (en) * 2009-05-21 2010-11-24 张作光 A group of pharmaceutical composition and preparation method for treating depression
CN101700289B (en) * 2009-11-02 2012-02-15 南京师范大学 Traditional Chinese medicine extract composition for treating gastrointestinal dysfunction or irritable bowel syndrome (IBS), and preparation method and applications thereof in preparation of medicaments
CN104984002B (en) * 2015-06-16 2018-05-29 成都乾坤动物药业有限公司 A kind of multi-functional Chinese and western medicinal composition for animals and preparation method thereof

Also Published As

Publication number Publication date
CN1579485A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
CN101623366B (en) Composition for curing gastrointestinal functional disorders, preparation method thereof and application thereof in preparing drugs for curing gastrointestinal functional disorders
CN1250255C (en) Chinese herbal medicine combination for treating disease of disorder of bowels&#39;s function and its product
Luo et al. Character and laxative activity of polysaccharides isolated from Dendrobium officinale
US20060110468A1 (en) Herbal formulations for arthritis
CN104491751B (en) A kind of fatty liver for the treatment of merges Chinese medicine composition of hyperlipidemia and preparation method thereof
CN102085252A (en) Pharmaceutical composition for treating ulcerative colitis and colon-targeted micro-pill preparation thereof
CN104013756A (en) Traditional Chinese medicine composition for preventing and treating diarrhea and application of traditional Chinese medicine composition
Yu et al. Overview of research on the application of medicine food homologous bioactive ingredients to functional constipation
CN102247479B (en) Antitumor strong medicine and preparation method thereof
CN1579485B (en) Traditional Chinese medicine composition for treating intestinal dysfunction and preparation method thereof
CN103933487A (en) Compound traditional Chinese medicament for treating depression
CN102526512B (en) Traditional Chinese medicine for treating motor complications of Parkinson&#39;s diseases and application thereof
CN111375035B (en) Preparation and application of enteric-coated preparation for treating cervical spondylosis
CN103316101B (en) Traditional Chinese medicine for treating diabetic nephropathy and preparation method thereof
CN102614283B (en) Medicament for promoting postoperative gastrointestinal function recovery and application of medicament
CN100415255C (en) A kind of traditional Chinese medicine composition and preparation method thereof
CN112402566B (en) Application of traditional Chinese medicine composition in preparation of medicine for treating gonarthromeningitis
CN101317900A (en) Traditional Chinese medicine composition for preventing and treating alcoholic liver injury and preparation method thereof
CN104998085A (en) Chinese herbal compound composition capable of enhancing immune function and preparation method thereof
He et al. Therapeutic potential of traditional Chinese medicine for the treatment of chemotherapy-induced diarrhea: Clinical efficacy and underlying mechanisms
CN103933386A (en) Compound hemophiliac capsule used for treating hemophilia and preparation method thereof
CN104095912A (en) Traditional Chinese medicine formula for treating rheumatism bone disease and preparation method of Chinese patent medicine of traditional Chinese medicine formula
CN102688254B (en) Medicinal composition for treating chronic diarrhea and preparation method and use thereof
CN112402565B (en) Traditional Chinese medicine composition for treating gonarthromeningitis and preparation method thereof
CN101549064B (en) Medicament composition containing chilopod acting on NEI network and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100428

Termination date: 20140316